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Molecular imaging is a key element of cancer management in the 21st century.  
Molecular imaging enables the visualization and characterization of cancer-specific 
events at the cellular and molecular levels in living systems. It allows cancerous 
lesions to be detected at an earlier stage, which is one of the most effective 
strategies for cancer treatment. In addition, it has a major impact on intra-operative 
cancer detection, the real-time validation of therapy, as well as the knowledge of the 
role of cancer-related components. Specifically, optical imaging is a highly sensitive 
and non-invasive molecular imaging technique, in contrast to anatomical imaging 
approaches.  
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Cancer research has been focused on studying and characterizing the genetically 
determined expression of biomolecules by cancer cells in the past several decades. 
For targeted cancer imaging, over-expressed receptors on the surface of cancer cells 
or over-produced enzymes by cancer cells have been utilized. However, genetic and 
epigenetic alterations in tumor cells have been found to be insufficient to offer 
tumor cells with malignant properties although they are prerequisites for malignant 
processes. In recent years, it has become obvious that other components of tumors, 
such as non-tumor cells (endothelial cells, fibroblasts), connective tissue, 
extracellular matrix (ECM), immune cells, and soluble factors play fundamental 
roles in tumor development and progression. These components are collectively 
known as the tumor microenvironment. Therefore, increased attention has been paid 
to the tumor microenvironment as well as cancer cells for cancer imaging.  
In this study, imaging probes were first developed to target and visualize the 
components of cancer cell or the tumor microenvironment; the probes were then 
applied for cancer imaging. In Chapter 2, cathepsin B (CB), an over-produced 
enzyme by cancer cells was targeted and visualized in metastatic tumor models. The 
fact that the activity of CB is markedly linked to the metastatic process and that CB 
is found highly expressed in the pericellular regions in this process makes CB an 
attractive target for diagnosing metastases. A CB-sensitive nanoprobe (CB-CNP) 
was developed to include CB-sensitive fluorescence peptide probes conjugated onto 
the surface of tumor-targeting glycol chitosan nanoparticles (CNPs). The 
fluorescence intensity of the CB-CNP was strongly quenched in physiological 
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condition. However, self-quenched CB-CNP boosted strong fluorescence signals in 
the presence of CB, not of cathepsin L or cathepsin D, due to the CB-specific 
cleavage of peptide probes. Importantly, the intravenously injected CB-CNP 
demonstrated the potential to discriminate metastases in vivo in three metastatic 
mouse models, including 4T1-luc2 liver metastases, RFP-B16F10 lung metastases 
and HT1080 peritoneal metastases. CB-CNPs may be useful for depicting 
metastases through the non-invasive molecular imaging of CB activity.  
In Chapter 3, an over-expressed receptor on the surface of cancer cells, epidermal 
growth factor receptor (EGFR), was targeted for cancer imaging. Herein, an 
epidermal growth factor-based nanoprobe (EGF-NP) was developed for the in vivo 
optical imaging of EGFR. The self-quenched EGF-NP is fabricated by sequentially 
conjugating a near-infrared (NIR) fluorophore (Cy5.5) and a quencher (BHQ-3) to 
EGF, a low-molecular weight polypeptide (6.2 kDa), compared to EGFR antibody 
(150 kDa). The self-quenched EGF-NP presented great specificity to EGFR, and 
rapidly internalized into the cells. Importantly, the self-quenched EGF-NP boosted 
strong fluorescence signals upon EGFR-targeted uptake into EGFR-expressing cells, 
followed by lysosomal degradation, as confirmed by lysosomal marker cell imaging. 
Consistent with the cellular results, the intravenous injection of EGF-NP into tumor-
bearing mice induced strong NIR fluorescence intensity in the target tumor tissue 
with high specificity against EGFR-expressing cancer cells. The signal 
accumulation of EGF-NP in tumors was much faster than that of EGFR monoclonal 
antibody (Cetuximab)-Cy5.5 conjugates due to the rapid clearance from the body 
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and tissue permeability of low-molecular weight EGF. This self-quenched, EGF-
based imaging probe can be applied to diagnose of various cancers.  
In Chapter 4, the detection of lysyl oxidase (LOX) activity in ECM was attempted 
using gold nanoprobes. Stiffness of ECM is significantly associated with cancer 
progression and malignancy. LOX is considered as an important factor to affect 
stiffness of ECM among various factors. In addition, LOX has been validated for a 
prognostic marker for metastasis and survival in multiple cancer types including 
head and neck squamous cell carcinoma. Therefore, a sensitive and simple assay for 
detecting the activity of LOX is needed. The plasmon coupling-based color change 
using AuNPs has been widely used to detect the presence or amounts of analytes 
that cause the selective aggregation of AuNPs. The AuNPs were functionalized with 
LOX-sensitive hexapeptides (LOX-AuNPs) to detect LOX. LOX-AuNPs turn from 
their original pinkish red to purple and the absorption spectra of the LOX-AuNPs 
red-shifted in correlation with the LOX concentration. In addition, LOX-AuNPs 
showed high specificity for LOX as presented in the experiments with LOX 
inhibitor or Control-AuNPs. LOX-AuNPs demonstrated the potential to detect LOX 
in cancer cells and tumor tissues including different LOX contents. LOX detection 
by LOX-AuNPs in cancer cells was more sensitive compared to those by a 
commercially available LOX assay or Western blot analysis. LOX levels measured 
using LOX-AuNPs in various tumor tissues were correlated directly with their 
collagen contents and their ECM stiffness. Therefore, LOX-AuNPs may be applied 
to detecting LOX activity and further ECM stiffness of tumor tissues.  
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Successful surgical procedures for cancer treatment depend on the accurate and 
rapid localization of tumor tissues, following their correct resection. In Chapter 5, 
tumor tissue-specific imaging by topical application was attempted for rapid tumor 
visualization. It was hypothesized that tissue-permeable probes can differently 
accumulated in tumor or normal tissue due to the structural difference between them. 
To make tissue-permeable probes, the factor of high volume of distribution (Vd) 
was utilized. The Vd can be calculated as the ratio of the total amount of a drug in 
the body and its concentration in the blood at a steady state. A higher Vd indicates 
that the drug is more diluted than it should be in the blood, suggesting that a larger 
amount of the drug has been distributed in the tissue, not in blood. Accordingly, the 
drug with high Vd can be tissue-permeable. Four drug-dye conjugates were 
synthesized by directly coupling the NIR dye, FCR675, with 4 drugs with different 
Vd values, including raloxifene (2348 l/kg), scopolamine (3.1 l/kg), ampicillin (0.38 
l/kg), and ibuprofen (0.15 l/kg). Drug-dye conjugates were topically applied via 
spraying on the liver surface of the HCT116 liver tumor-bearing mice and 
transanally applied via the anus into the descending colon of colon tumor-bearing 
mice. Topically applied Ralo-FCR675 also rapidly penetrated to the tumor’s 
maximum depth and, more importantly, Ralo-FCR675 preferentially accumulated in 
the tumor lesions within 3 min. Vd could be a factor to differentiate between tumor 
tissue and non-tumor tissue. Fluorescently labeled drugs with high Vd, such as 
raloxifene may be useful for the rapid visualization of tumors, contributing to 
successful surgical procedures for cancer treatment. 
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Finally, in Chapter 6, tumor-associated macrophage (TAM) was targeted and 
visualized. Specifically, TAM infiltration into tumors has been strongly correlated 
with poor prognosis in multiple cancer types. Hence, the imaging of TAM 
infiltration in tumors could be helpful in clinical applications for the prognosis and 
treatment of tumors. Scavenger receptors class A (SR-A) is known to be highly 
expressed in the TAMs of multiple cancer types and to be recognized with various 
negatively charged macromolecules including dextran sulfate (DS). Herein, 
FPR675-labeled DS nanoprobes (DSNPs) were developed to detect TAMs. DSNPs 
were significantly uptaken into RAW264.7 macrophage cells and isolated TAMs, 
not in MDA-MB-468 cancer cells. In an MDA-MB-468 subcutaneous tumor model, 
DSNPs provide high fluorescence signal both in tumor and liver sites. Further 
immunohistochemical analyses demonstrated that DSNPs mainly target CD204-
positive TAMs. Therefore, DSNPs could be potentially utilized to visualize TAM 
infiltration in tumors. 
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Cancer is a serious global health challenge.1 According to the World Health 
Organization, cancer is a leading cause of death worldwide, accounting for 8.2 
million deaths in 2012, and this number is predicted to increase to 12 million by 
2030.2, 3 Most cancer occurs because of abnormal cell division induced by complex 
interactions between the host genome and carcinogens. These abnormalities in cell 
division often lead to the formation of tissue mass called tumors. Tumors may be 
classified as either malignant (cancerous) or benign (noncancerous). A malignant 
tumor is capable of invading normal tissues and organs adjacent to the location of 
the primary tumor, thereby impeding the normal function of the body’s system. 
However, cancer cells detach from a primary tumor and spread through the blood 
circulation and lymphatic system to distant spots in the body, developing new 
tumors; this process is called metastasis. Eventually, malignant tumors can destroy 
various organs in the body, leading to death.   
Cancer research over the past few decades has been focused on understanding the 
transformation of normal cells to cancer cells. However, scientists spent little time 
researching other types of cells present within a tumor. Although genetic and 
epigenetic alterations in tumor cells are prerequisites for the malignant process, they 
are not sufficient to offer tumor cells with malignant properties. Complex 
interactions between different host cell types and cancer cells form a dynamic tumor 
microenvironment that closely interacts with cancer cells.4 Many lines of evidence 
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support that the intimate association between cancer cells and their tumor 
microenvironment deeply influences cancer development and progression and 
affects many hallmarks of cancer.5-7 Therefore, attention needs to be paid to the 
tumor microenvironment as well as cancer cells in the fight against cancers. 
 
1.2. Molecular imaging in cancer management 
Molecular imaging enables the visualization and characterization of cancer-
specific events at the cellular and molecular levels in living systems. Many features 
of the malignant process can be visualized with molecular imaging, involving 
changes in gene expression, the neovasculature of angiogenesis, the expression of 
receptors on cancer cell surfaces, and changes of extracellular matrix or stromal 
cells in the tumor microenvironment. Molecular imaging has several advantages for 
cancer management.8  
First, it could facilitate the detection of cancerous lesions at an earlier stage. 
Detecting cancer at an earlier stage is one of the most significant strategies to 
reduce both mortality and cancer incidence worldwide.1 Since molecular or cellular 
changes often happen a long time before any signs of structural, functional, 
anatomical changes become evident, molecular imaging can provide additional 
information about molecular and cellular events associated with diseases and 
facilitate earlier diagnosis in the course of a disease. In cancer, the detection and 
treatment of cancer before metastasis enhance one’s possibility of survival; when 
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detected at an early stage, cancer treatment is simpler and more effective. For 
example, the 5-year survival rate for patients who are diagnosed with breast cancer 
that has not yet spread from the breast tissue is approximately 99%. However, the 
survival rate for patients whose cancer has already spread to lymph nodes is 
approximately 84%, and that for patents whose cancer has spread to distant parts of 
the body including the liver, lungs or bones decreases to 23%.9 Moreover, this 
detection can non-invasively be achieved without biopsies or surgical procedures, 
which allows the repetitive measurement of the same living subject at different time 
points.  
Second, molecular imaging techniques could aid surgeons in delineating the 
margins of a tumor mass for tumor resection and appropriate biopsy. Successful 
surgical procedures depend on detecting the accurate and rapid localization of tumor 
tissues.10 The intra-operative detection of tumor lesions in real-time can allow 
complete tumor resection while preserving important structures, improving 
treatment outcome and reducing healthcare costs.11  
Third, molecular imaging techniques enable the real-time validation of therapy.12 
Real-time, noninvasive monitoring can allow clinicians to identify positive or 
negative patient response to the current therapeutic regimen and to guide decisions 
on the continuation or alteration of the regimen before evaluating traditional 
treatment efficacy, such as a change in tumor size. For example, clinicians can 
switch to other therapeutic options, or they can adjust the therapeutic dose for non-
responders to the current therapeutic regimen, while continuing the therapy for good 
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responders. This is especially significant because treatment using monoclonal 
antibodies, such as cetuximab and trastuzumab is increasing.13  
Finally, molecular imaging can increase the knowledge of the role of cancer-
related components throughout the course of the disease. Such knowledge can 
broaden understanding of how distinct components can be under control, 
contributing to the creation of more effective treatment against cancer. In addition, 
this can lead to the development of more advanced probes and imaging methods to 
image characteristics and activities of distinct components.  
 
1.3. Cancer imaging modalities 
Presently, various imaging modalities are available for diagnosis, staging, and 
treatment of cancer: optical imaging, ultrasound (US) imaging, magnetic resonance 
(MR) imaging, computed tomography (CT) and nuclear imaging (single photon 
emission computed tomography (SPECT), and positron emission tomography 
(PET)). These modalities can be broadly separated into primarily molecular imaging 
modalities and primarily morphological/anatomical imaging modalities.14 The 
former, which are characterized by high sensitivity, include optical imaging and 
PET/SPECT; on the other hand, the latter, which are featured by high spatial 
resolution, include CT, US, and MR.14, 15 However, those imaging modalities have 
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resolution (Figure 1.1). 
 
Computed tomography  
CT is a widely performed modality in diagnosis and staging of nearly all cancer, 
and also the initial comprehensive imaging performed in patients with suspected 
cancer.16 CT is used to detect different densities of X-ray absorption in different 
tissues when x-rays pass through a patient’s body.17 It has an inherent high-contrast 
resolution, which allows the discrimination of tiny differences between body tissues 
with various physical densities. However, the soft tissue contrast of CT is low, 
which could cause difficulties when detecting cancer invasion into surrounding 
structures or distant metastases.18 In addition, exposure to ionizing radiation during 
a CT scan is the most serious weakness, because it could harm patients, specifically 
to children. However, CT has still many advantages, therefore, it has frequently 
been utilized in clinical diagnosis.  
 
Magnetic resonance imaging 
MR imaging displays great promise for detecting cancers and for defining the 
extent of a cancer’s spread. MR imaging produces anatomical images of organs 
with surpassed soft tissue differentiation compared to any other imaging method, 
which enables accurate cancer detection and local staging. MR imaging detects the 
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spin of the hydrogen nucleus, which are predominantly contained in the water and 
fat of the human body. During the MRI examination, nuclear spins are subjected to 
a selective radio-frequency pulse, and then nuclei in the excited state will “relax” 
and return to their initial state. This process, called relaxation, involves spin-lattice 
relaxation time (T1) and spin-spin relaxation time (T2), both of which can be used to 
produce an MR image capable of distinguishing between various types of tissue. 
MRI examination is expensive and time-consuming, but MR imaging is 
advantageous in high contrast resolution between different soft tissue types and 
superior three-dimensional spatial resolution.  
 
Nuclear imaging  
Nuclear imaging modalities, including PET and SPECT, remotely visualize 
molecular events in cancer progression by observing radioactive emission from 
targeted radiolabelled probes.19, 20 They provide quantitative images of the three-
dimensional distribution of injected short-lived radiolabelled probes in vivo. 
Radiolabelled probes can be constructed using monoclonal antibodies against 
cancer cell-specific antigen, which has been widely used in imaging of several 
cancer types. Common positron-emitting radioisotopes for PET involve 11C, 18F, 13N, 
15O, and 124I, while common γ-emitting isotopes for SPECT include 99mTc and 
111In.21 Cancer imaging by PET with the tracer 18F-fluorodeoxyglucose (18F-FDG) is 
commonly utilized in clinics, which is based on increased uptake of 18F-FDG in 
metabolically active proliferative tissue such as cancer. Some studies reported that 
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PET is useful in finding small metastases that is missed by CT.16 The sensitivity of 
PET is particularly superior to that of SPECT. On the other hand, SPECT allows the 




US imaging is a well-established imaging technique used in clinical settings for 
diagnosing several cancer types such as breast, prostate, and pancreatic cancer. US 
enables demonstration of zonal anatomy and determination of cancer size. US 
imaging utilizes high-frequency ultrasound waves. The ultrasound waves 
transmitted from a transducer are reflected back by the target organs in a patient’s 
body, endowing reconstructed images of scanned areas. US imaging is mainly a tool 
used to provide highly detailed, real-time visualization of anatomy and physiology 
in clinical diagnosis. US imaging has benefits in that it is safe, fast, and inexpensive. 
However, the ultrasound waves are disrupted by gas or air; US has limitations in 
visualizing air-filled bowel or gas-containing organs like the lungs. In addition, US 
has difficulties in penetrating bone; therefore, US imaging cannot see the interior of 
bony structures. Recently, contrast-enhanced US with micro/nanobubbles has been 




Optical imaging based on bioluminescence or fluorescence is a sensitive imaging 
technology for diagnosing and staging of cancer and follow-up care after cancer 
treatment. Optical imaging used light to probe molecular targets and gene reporters 
in the context of cancer in a living subject. Bioluminescence imaging measures the 
light emitted by the chemical reaction between a luciferase enzyme and luciferin. In 
addition, fluorescence imaging detects the light emitted from a fluorophore at a 
particular wavelength after excitation light typically illuminates the area of interest. 
The advantages of optical imaging include sensitivity, real-time and convenient use, 
and non-ionization safety. However, it has a low penetration depth due to strong 
absorption in the visible light region. This is the main reason that near-infrared (NIR) 
fluorescent light (λ=650-900 nm) is used, especially in in vivo imaging. The use of 
fluorophores within this range allows for low levels of interfering autofluorescence 
and high tissue penetration (up to several centimeters deep) in living tissues, 
providing enhanced image contrast with high sensitivity. Because of the availability 
of multicolor imaging involving different fluorophores, optical imaging would be 
very popular and powerful when capturing the various biological status of different 
tissues with regard to cancer heterogeneity.23 The use of optical imaging can be also 
applied for delineating the margins of a tumor mass for tumor resection and 
appropriate biopsy as well as screening for cancer. 
No single imaging modality simultaneously provides sufficient sensitivity and 
temporal and spatial resolution for cancer diagnosis. Hence, integrated molecular/ 
anatomical systems have recently been exploited to combine the strengths of 
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individual imaging modalities. For example, PET imaging provides high sensitivity, 
but not anatomical information. Hence, PET imaging has been integrated with CT 
which allows anatomical information with high spatial resolution. Indeed, an 
integrated PET/CT system is commercially available now and is routinely utilized 
for diagnosing and staging of cancer, and follow-up care of cancer treatment in 
clinical settings.24 
 
1.4. Targets of cancer cells for cancer imaging 
Some cancer cells produce over-expressed receptors on their surface compared to 
normal cells.25 For several decades, over-expressed receptors on the surface of 
cancer cells have been researched as primary targets for tumor imaging and therapy. 
These include human epidermal receptors, transferrin receptors, and folate 
receptors.3  
 
Epidermal growth factor receptor  
Epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor 
tyrosine kinases.26, 27 EGFR is known to activate multiple cell signaling pathways 
that promote cell growth in response to the binding of its specific ligands, including 
transforming growth factor-α (TGF-α) and epidermal growth factor (EGF). These 
ligands bind directly to EGFR; therefore, these ligands can act as targeting moieties 
for EGFR. EGFR is shown to be overexpressed in many types of cancers, including 
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non-small cell lung cancer, skin cancer, breast cancer, small cell carcinoma of head 
and neck, and prostate cancer. In fact, one-third of all solid tumors is known to 
express EGFR.28 The overexpression of EGFR is shown to be correlated with poor 
prognosis and increased metastatic potential. 
 
Transferrin receptors 
Transferrin receptors are membrane-associated glycoproteins that function in the 
regulation of cell growth and the cellular uptake of iron and by binding with 
transferrin.29 Iron is an essential cofactor of various proteins involved in cellular 
processes such as metabolism and DNA synthesis. When binding to the transferrin 
receptors on the plasma memebrane, the transferrin is internalized via receptor-
mediated endocytosis, and trasferrin receptors recycle onto the cell surface. The 
transferrin receptors are shown to be overexpressed in many types of cancers, 
including glioma, bladder-trasitional cell carcinomas, lung adenocarcinoma, breast 
cancer, and chronic lymphocytic leukemia. Transferrin receptors are very attractive 
targets for cancer targeting because they are known to be overexpressed on drug-
resistant or metastatic cells.30 
 
Folate receptors 
Folate receptors, glycosylphosphatidylinositol-anchored cell surface receptors, are 
one of the most widely investigated targets for cancer targeting.31 Folate receptors 
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facilitate the transportation of folate into the cytoplasm of cells. Folate is necessary 
for essential cell functioning because it is involved in the synthesis of pyrimidines 
and purines. Folate receptors are expressed in nearly all cells for normal cell 
division as well as DNA replication. However, they are expressed in a much greater 
amount in tumor cells than nontumor cells. In particular, they are highly 
overexpressed on the vast majority of cancers including ovarian, brain, lung, and 
breast cancers. Folate is widely used as a targeting ligand for folate receptors 
because of its low cost, high binding affinity, high stability in blood, and low 
toxicity.32  
 
1.5. Targets of the tumor microenvironment for cancer 
imaging 
In recent years, it has become obvious that other components of tumors, such as 
non-tumor cells (endothelial cells, fibroblasts), connective tissue, extracellular 
matrix (ECM), immune cells, and soluble factors play fundamental roles in tumor 
development and progression.33 These components are collectively known as the 
tumor microenvironment. New strategies for tumor imaging or therapy have been 
established by targeting the tumor microenvironment instead of targeting tumor 
cells.34 Unlike tumor cells, cellular components in the tumor microenvironment are 
genetically stable, which makes the tumor microenvironment attractive therapeutic 


















Targets of the tumor microenvironment for tumor imaging can be grouped into two 
categories: cellular components and non-cellular components. 
 
1.5.1. Cellular components of the tumor microenvironment 
Blood-vessel cells such endothelial cells and pericytes, CAFs, and immune cells 
are key players among the cellular components of the tumor microenvironment.  
 
Blood vessel cells  
Angiogenesis-associated targeting has become attractive for cancer imaging and 
therapy. Blood vessels promote tumor growth by delivering sufficient oxygen and 
nutrients. In fact, most tumors cannot expand a few mm3 in volume and maintain 
clinically silent in the absence of blood-vessels.37 Tumor angiogenesis is the multi-
step process of new blood vessels from pre-existing vasculature, which is mainly 
mediated by the invasion, migration, and proliferation of endothelial cells. Host 
cells and tumors secrete a variety of pro-angiogenic growth factors and anti-
angiogenic growth factors, which could bind to their receptors on the surface of 
endothelial cells. These specific bindings between growth factors and their receptors 
mediate and regulate angiogenesis. Pericytes are contractile cells that surround the 
endothelial cells of blood vessels, which provide vascular stability and mediate 
endothelial proliferation. Tumor blood vessels are known to be leaky and irregularly 
dilated, unlike normal blood vessels. These properties of tumor blood vessels are the 
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primary reason to utilize nanoparticles (NPs) for tumor targeting. NPs can easily 
extravasate from blood vessels into tumor tissues because of leaky and irregularly 
dilated blood vessels at tumor sites, and they can also be retained at tumor sites 
owing to poor lymphatic drainage. This phenomenon of the selective accumulation 




CAFs comprise a majority of the cells in tumor stroma. They can derive from 
normal fibroblasts as well as from excessive progenitor cells including bone 
marrow-derived cells, endothelial cells through the process of endothelial-to-
mesenchymal transition, and cancer cells through the process of epithelial-to-
mesenchymal transition. CAFs produce a series of growth factors such as 
eptidermal growth factor (EGF) and vascular endothelial growth factor (VEGF), 
cytokines such as interleukins and proteases such as matrix metalloproteinases 
(MMPs), which sustain cancer progression.38 In addition, they synthesize a diversity 
of ECM components including fibronectin, tenascin, and collagens to regulate 
tumor cell proliferation, angiogenesis, and cancer metastasis. Increasing evidence 
indicates that interactions between tumor cells and CAFs are essential for cancer 
development and progression, which makes CAFs attractive targets for tumor 
imaging and therapy.39, 40 
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Immune cells 
Immune cells, including lymphocytes, macrophages, natural killer cells, and 
dendritic cells are important for tumor suppression. However, diverse suppressor 
cells such as TAMs, regulatory T cells, and myeloid-derived suppressor cells are 
recruited to the tumor microenvironment.41 These cells negatively regulate immune 
response, helping tumor cells avoid the attack by immune effector cells.42 
Accumulated evidence has demonstrated that tumor-associated immune cells can 
secret cytokines, growth factors, chemokines, and matrix-degrading proteases, such 
as MMPs, cathepsin proteases, and heparanses, which provide favorable conditions 
for tumor cell proliferation, angiogenesis, and cancer metastasis. By producing 
these cytokines, growth factors, and proteases, immune cells in the tumor 
microenvironment work as essential mediators in sustaining cancer progression. 
 
1.5.2. Non-cellular components of the tumor microenvironment 
Extracellular matrix 
The ECM, a multifunctional interstitial matrix, consists mainly of collagens, 
elastin, laminin, fibronectin, and proteoglycans. Because it has an important role in 
conferring shape and stability to tissues, ECM ubiquitously exists in human tissues. 
However, its composition can vary according to its location and function.43 In 
cancer, the ECM is not a static structure to maintain tissue morphology and 
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constantly undergoes remodeling. Highly dynamic ECM can result from the 
modified composition or density of the ECM. The ECM in tumor tissues commonly 
includes a much denser and thicker network consisting of different composition 
compared to normal tissues.44 Specifically, the ECM is typically deregulated and 
becomes abnormal, which directly influences cancer progression by encouraging 
transformation and metastasis.45 In addition, abnormal ECM also deregulates 
surrounding stromal cells and promotes tumor-associated angiogenesis, which 
continuously creates favorable conditions to accelerate tumor malignancy and 
metastatic progression. Because the ECM is not enclosed by a plasma membrane, 
imaging probes or drugs have essentially unlimited access to these areas.46 This can 
be the most crucial benefit of approaches to target ECM.  
 
Matrix-degrading enzymes 
Matrix-degrading enzymes including MMPs, cysteines, plasminogen activators, 
and other hydrolases are over-produced by tumor cells, CAFs, or TAMs.47 MMPs 
are a group of over 20 enzymes facilitating the degradation of the ECM and the 
basement membrane. By degrading the ECM, especially type IV collagen and 
laminin, MMPs enable the invasion and migration of tumor cells as well as 
endothelial cells and immune cells to surrounding tissues. Besides degradation of 
the ECM, MMPs can promote the release of angiogenic cytokines, such as VEGF, 
and the homing of bone marrow-derived circulating endothelial progenitor cells, 
which contributes to successful angiogenesis.48 Cathepsins are a group of 11 
19 
enzymes belonging to the papain family of cysteine proteases.49 Among various 
cathepsins, cathepsin B is known to play an important role in the growth, migration, 
invasion, and metastasis of various cancers.50, 51 In addition, some reports on solid 
tumors have shown a correlation between the expression of cathepsin B and tumor 
progression/clinical outcomes in patients.52 
 
Soluble factors 
A variety of soluble factors are produced and secreted by stromal and tumor cells 
in the tumor microenvironment.53 These over-expressed soluble factors engage in a 
wide range of signaling pathways and influence tumor behavior upon binding to 
their receptors. For instance, VEGF plays a significant role in initiating tumor 
angiogenesis.54, 55 VEGF potentiates microvascular hyperpermeability which 
enables to both precede and accompany angiogenesis by stimulating an influx of 
endothelial cells, fibroblasts, and inflammatory cells. Upon binding to its specific 
receptor, moreover, VEGF promotes the expression of Bcl-2 and signaling through 
chemokines (CXCL1 and CXCL8), resulting in the proliferation and migration of 
endothelial cells and the formation of new blood vessels. Activated fibroblasts that 
encourage a microenvironment conducive to tumor progression are mediated by 
various soluble growth factors including fibroblast growth factor-2, platelet-derived 
growth factor, and transforming growth factor-β (TGF- β).56 Tumor cells may alter 
their stroma by a wide range of soluble factors.57 
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Integrins 
The tumor microenvironment includes a large group of cell adhesion receptors 
called integrins, which are involved in cell-cell and cell-ECM interactions.58 
Intergrins consist of different combinations of two transmembrane glycoprotein (α 
and β) subunits and are overexpressed in various cell types of tumors. For example, 
ανβ3 integrin is one of extensively investigated targets for tumor targeting. To target 
ανβ3 integrin, the peptide possessing high affinity for ανβ3 integrin, arginine-glycine-
aspartic acid (RGD) sequence, was widely utilized.59 ανβ3 integrin is upregulated on 
proliferating tumor cells and activated endothelial cells, but is minimally expressed 
in cells in most normal organ systems and in resting or normal endothelial cells. 
ανβ3 integrin can influence the survival, migration, and invasion of tumor cells, 
mediating interaction between tumor cells and ECM proteins. 
 
1.6. Scope of this thesis 
Even with the recent advances in diagnosis and management of many cancers, 
cancer modality rates still remain high. By employing a more sensitive and more 
specific imaging technique, earlier diagnosis and more accurate assessment of 
prognostic factors of cancer are possible. It ultimately improves patient care. In 
particular, for the imaging to be more effective, cancer should be considered as a 
multi-factorial disease, resulted from the combined influence of many genetic 
factors acting in concert with the environmental change. The combination of 
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information using results from multiple target-specific molecular imaging will 
improve the sensitivity and specificity in the diagnostic process of cancer. 
This dissertation seeks to visualize the key components of the evolving cancer 
burden during cancer development and progression. Various key components of the 
evolving cancer burden were selected: the over-produced protease, the over-
expressed receptors on the surface of cancer cells, the tumor-associated 
macrophages in the tumor microenvironment, the extracellular matrix-remodeling 
enzymes, and the modified tumor tissues. To visualize specific components, new 
imaging probes were developed based on appropriate materials targeting the cancer-
specific components – a peptide, a protein, a commercial drug, a gold nanoparticle, 
or a polymer. Although this work focuses on applying the targeting abilities of the 
probes to visualize the targets, the specific abilities developed here offer new 
opportunities as a platform for therapeutic use. I performed the cancer-specific 
imaging with hopes to translate this work to a clinical setting and help patients in 
need of personalized treatment options.  
The specific goals of this thesis are as follows: 
· To develop peptide-based activatable probes for non-invasive imaging of 
metastasis 
· To develop protein-based activatable probes with potential use for therapeutic 
monitoring 
· To visualize the infiltration of tumor-associated macrophages with polymer-based 
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probes 
· To detect ECM-modifying enzymes with gold nanoparticle-based probes 
· To develop a rapid method for determining tumor mass in the operating room 
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An important determinant of cancer patients’ treatment is the absence or presence 
of metastasis.1 The progression of cancer from a primary tumor to metastasis occurs 
at widely different rates for various tumors.2 Though the rate of this progression 
may be dissimilar among tumors, many tumors undergo a series of steps that lead to 
cellular- or molecular level changes prior to or during metastasis. Identifying 
molecular changes prior to or during metastasis could help in diagnosing early 
metastases, contributing to the early initiation of therapy and ultimately the 
improved survival of patients. Most studies have demonstrated the characterization 
of molecular changes in vitro; however, few researchers have attempted to visualize 
molecular changes in vivo for metastasis.3 Therefore, there is an urgent need for 
imaging techniques that are capable of depicting metastases in vivo by detecting 
molecular changes associated with metastasis.  
High levels of secretion of cathepsin B (CB) into the pericellular region are 
important for cancer invasion and metastasis.4, 5 In the metastatic process, the 
proteolytic degradation of extracellular matrices (ECMs) is required because 
malignant cancer cells invade basement membranes, spread to distant sites, and 
subsequently reinvade and grow at new location in the body. Various proteases have 
been implicated in cancer invasion and metastasis, including cathepsins, 
plasminogen activators (PA), and matrix metalloproteinases (MMPs). CB activates 
PA, which then converts plasminogen to plasmin. Plasmin in turn activates latent 
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MMPs, turning them into activated MMPs. That is, CB is highly expressed in the 
early stage of the proteolytic cascade involved in cancer invasion and metastasis.6 In 
addition, active forms of CB normally remain in the lysosomal compartments inside 
mammalian cells; however, as cells obtain metastatic potential, CB is highly 
expressed in the pericellular region.7 Therefore, pericellular CB activity detection 
can facilitate the early diagnosis of metastases.  
CB activity detection could be a favorable approach to diagnose metastases. A 
CB-sensitive nanoprobe (CB-CNP) consisting of CB-sensitive fluorescence peptide 
probes conjugated onto the surface of tumor-targeting glycol chitosan nanoparticles 
(CNPs) was developed to detect the activity of CB.8 In addition, three metastatic 
mouse models were induced, including 4T1-luc2 liver metastases, RFP-B16F10 
lung metastases, and HT1080 peritoneal metastases. CB expression in various 
tumor models was confirmed by immunohistochemistry (IHC) or Western blot. 
Importantly, the potential use of intravenously injected CB-CNPs for discriminating 
metastases in vivo was investigated (Figure 2.1). The CB-CNP’s in vivo specificity 
was also evaluated by treating CB inhibitor in an HT29 subcutaneous tumor mouse 
model. Then, CB-CNP’s detection sensitivity was compared with that of CNP-
Cy5.5 without CB-sensitive moiety in an HT29 liver tumor model.  
 




























































Cy5.5 N-hydroxysuccinamide (NHS) ester (Cy5.5-NHS, excitation and emission  
maximum of 675 nm and 693 nm, respectively) was purchased from GE Healthcare 
(Piscataway, NJ) and black hole quencher 3 NHS ester (BHQ3-NHS, absorbance 
maximum of 672 nm) was obtained from Biosearch Technologies, Inc. (Novato, 
CA). CB, cathepsin D and cathepsin L enzymes were purchased from R&D Systems, 
Inc. (Minneapolis, MN). Cathepsin inhibitor (Z-Phe-Ala-FMK) was purchased from 
Calbiochem (San Diego, CA). Monoclonal mouse anti-CB IgG and goat anti-mouse 
IgG-FITC were purchased from Abcam (Cambridge, MA) and Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA), respectively. Fetal bovine serum (FBS) was 
purchased from Invitrogen Canada (Burlington, ON, Canada), and RPMI 1640 
medium and Dulbecco's modification of Eagle's medium (DMEM) were obtained 
from Gibco (Grand Island, NY). For Western blot, anti-CB and a horseradish 
peroxidase-conjugated anti-mouse antibody were purchased from Calbiochem and 
Santa Cruz Biotechnology, respectively.  
 
2.2.2. Preparation of the cathepsin B-sensitive nanoprobe  
The CB-peptide probe was developed by linking a near infrared (NIR) fluorophore 
(Cy5.5) and a dark quencher (BHQ-3) to a CB-sensitive substrate peptide (Gly-Arg-
Arg-Gly-Lys-Gly-Gly; the recognition site is italicized and the cleavage site was 
between Arg and Gly).8 Peptides were synthesized using a standard solid-phase 
32 
peptide synthesis method (Peptron, Daejeon, Korea). Next, the CB-peptide probes 
were chemically linked onto the surface of the self-assembled chitosan 
nanoparticles (CNPs) to develop the cathepsin B-sensitive chitosan nanoprobe (CB-
CNP). Briefly, glycol chitosan was conjugated with hydrophobic 5-cholanic acid 
(150  5 molecules of 5-cholanic acid per glycol chitosan).9 The glycol chitosan 
conjugated with 5-cholanic acid (22 nmol) was dispersed in phosphate-buffered 
saline (PBS, 7 ml) using a probe-type sonicator (90 W, 5 min, Ultrasonic Processor, 
GEX-600; Sonics & Materials, Newtown, CT), resulting in CNP solution. The CB-
peptide probe (1.2 μmol) was dissolved in a co-solvent of dimethyl sulfoxide 
(DMSO) and PBS (1:1, v/v; 200 μl), and mixed with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and sulfo-NHS dissolved in PBS (100 μl) 
for 15 min. Then, these activated CB-peptide probes were mixed with CNP solution 
at room temperature (RT) in the dark for 12 h. After dialysis against distilled water 
(DW) and lyophilization, the CB-CNP (molecular weight 345 kDa) was obtained as 
blue powder. Meanwhile, CNP-Cy5.5 was synthesized by mixing Cy5.5-NHS with 
CNP solution at RT in the dark for 12 h. 
 
2.2.3. Characterization of cathepsin B-sensitive nanoprobe 
The mean diameter and size distribution of the CB-CNP were observed with 
dynamic light scattering (DLS) at 25C. The CB-CNP’s morphology in DW (1 
mg/ml) was assessed with transmission electron microscopy (TEM, CM30 
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electronmicroscope, Philips, CA). TEM analysis was performed at 200 kV. The 
sample solution was placed on the grid for 2 min and excess of sample solution was 
blotted with filter paper. For staining, the grid was placed on a drop of 2% (w/v) 
uranyl acetate. UV/Vis absorbance of CB-CNP (0.8 μM) and CB-peptide probes at 
various concentrations (2.5, 5.0, 10, 20 μM, respectively) was recorded from 450 to 
800 nm using UV/Vis spectrophotometer (Optizen 2120, Mecasys, Daejeon, Korea). 
The absorption intensity of BHQ-3 (690 nm) was measured, and the concentration 
of conjugated CB-peptide probe in CB-CNP was calculated from standard curve 
made by various concentration of CB-peptide probe.  
 
2.2.4. In vitro enzyme specificity 
In vitro CB enzyme specificity of the CB-CNP was examined by incubating the 
CB-CNP with CB, cathepsin L, cathepsin D, or CB plus inhibitor. The CB-CNP (20 
nM) was incubated for 50 min in an assay buffer [25 mM of 2-(N-morpholine)-
ethanesulphonic acid (MES)] containing 3.0 nM of CB, in an assay buffer (0.1 M of 
sodium acetate, 0.2 M of NaCl, pH 3.5) containing 23 nM of cathepsin D, or in an 
assay buffer (50 mM of MES, 5 mM of DTT, pH 6.5) containing 1.0 nM of 
cathepsin L, respectively. Fluorescence intensity was measured with a 
spectrofluorometer (F-7000 Fluorescence Spectrophotometer, Hitachi, Tokyo, Japan) 
every 10 min for 50 min at 37C. The excitation wavelength was 675 nm, and the 
emission intensity was measured at 693 nm. In addition, the CB-CNP (20 nM) was 
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incubated in 25 mM of MES buffer containing different concentrations (0, 1.0, 2.0, 
4.0, 8.0 nM) of CB enzyme for 50 min. 
 
2.2.5. Cytotoxicity 
Murine squamous cancer cells (SCC7), human colon cancer cells (HT29), 
enhanced firefly luciferase (luc2) gene-transfected mouse mammary gland tumor 
cells (4T1-luc2), and red fluorescence protein (RFP) gene-transfected mouse 
melanoma cells (RFP-B16F10) were maintained in RPMI 1640 medium containing 
10% (v/v) FBS and penicillin G (100 U/ml)/streptomycin (100 μg/ml) at 37C, 5% 
CO2. Human fibrosarcoma cells (HT1080) and mouse embryonic fibroblast cells 
(NIH3T3) were maintained in DMEM containing 10% (v/v) FBS and penicillin G 
(100 U/ml)/streptomycin (100 μg/ml) at 37C, 5% CO2.  
The CB-CNP’s cytotoxicity was evaluated using Cell Counting Kit-8 (CCK-8) 
assay. In brief, four kinds of cells, HT29, 4T1-luc2, RFP-B16F10 and HT1080 (1  
104 cells/well) were seeded in a 96-well microplate, and cultured for 24–36 h. The 
CB-CNP concentrations (5, 10, 25, 50, 100 μg/ml) were added to each well of the 
cell culture and incubated for 24 h. CCK-8 solution was added to each well of the 
cell culture and incubated for 2 h, and absorbance was observed at 450 nm with a 
plate reader. Cell viability was expressed as a percentage relative to the untreated 
control cells.  
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2.2.6. Cellular uptake and immunocytochemistry  
SCC7 cells (1×104 cells/dish) were plated in 35 mm cover-glass bottom dishes and 
grown to 80% confluence. The cells were washed twice with PBS (pH 7.4), and 
then incubated with serum-free medium containing CB-CNP (200 nM) and 
cathepsin B substrate peptide probe with same amount of Cy5.5 in the presence or 
absence of inhibitors for 6 h. The inhibitor was treated 30 min before CB-CNP 
incubation. The cells were washed with PBS (pH 7.4) twice, fixed with fresh 4% 
(v/v) paraformaldehyde at room temperature for 5 min, and mounted with 
Fluoromount-G™ (Southern Biotech, Birmingham, AL). Cellular uptake of the 
probes were observed using IX81-ZDC focus drift compensating microscope 
(Olympus, Tokyo, Japan) equipped with a 673-nm excitation filter and a 692-nm 
emission filter.  
Five kinds of cells were plated in 35 mm cover-glass bottom dishes and incubated 
for 48 h. The CB-CNP (200 nM) was treated in each cell culture and incubated for 2 
h. After incubation, the cells were washed with PBS and fixed in 4% (v/v) 
paraformaldehyde at RT for 10 min. The antigens were retrieved in the buffer (100 
mM Tris, pH 9.5, urea [5%, w/v]) at 95C for 10 min, and the cells were 
permeabilized with Triton X-100 (0.25%, w/v) for 5 min in PBS. Permeabilized 
cells were treated with monoclonal mouse anti-CB IgG (1:150 dilution) for 2 h and 
then with goat anti-mouse IgG-FITC (1:1500 dilution) for 30 min. Then, the cells 
were stained with 4',6-diamidino-2-phenylindole (DAPI). The samples were 
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observed with an IL-70 microscope (Olympus, Tokyo, Japan) equipped with a 
mercury arc lamp, a digital camera (Roper Scientific, Tucson, AZ), and optical filter 
sets (Omega Optical, Battleboro, VT). 
 
2.2.7. Tumor models 
All animal experimental procedures were in compliance with the institutional 
guidelines of Korea Institute of Science and Technology and the relevant laws. Five 
tumor models were utilized in this study. All tumors were induced in male athymic 
nude mice (20 g, Orient, Korea), and mice were anesthetized with an intraperitoneal 
injection of xylazine (10 mg/kg body weight) and ketamine (80 mg/kg body weight). 
For the induction of subcutaneous tumors, mice were anesthetized and SCC7 cells 
(1  106 cells/mouse) or HT29 cells (7  106 cells/mouse) suspended in 100 l 
sterile saline were subcutaneously injected into the flank of athymic nude mice, 
respectively. When subcutaneous tumors reached 5.0 ± 0.5 mm in diameter, the 
mice were utilized for imaging. The CB inhibitor was intratumorally injected 30 
min before the CB-CNP administration. To induce liver tumors, mice were 
anesthetized, a paramidline abdominal incision was made, and the liver was 
exposed. Then, HT29 cells (3  105 cells/mouse) suspended in 20 l of sterile saline 
were injected into the left lobe of the liver under the capsule.9 After injection of the 
cells, the paramidline incision was sutured. Seven days after the injection of HT29 
cells into the liver, the mice were utilized for imaging. To induce liver metastases, 
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mice were anesthetized, an incision on a left lateral flank was made, and the spleen 
was exposed. Then, 4T1-luc2 cells (3  105 cells/mouse) suspended in 30 l of 
sterile saline were injected into the spleen.10, 11 After injection of the cells, the 
incision was sutured. At 10 to 14 days after the injection of 4T1-luc2 cells, the mice 
were utilized for imaging. For the lung metastases, RFP-B16F10 cells (3  105 
cells/mouse) suspended in 50 l of sterile saline were injected into the tail vein.9, 12 
Fourteen days after the injection of RFP-B16F10 cells, the mice were utilized for 
imaging. For the peritoneal metastases, HT1080 cells (3  105 cells/mouse) 
suspended in 300 l of sterile saline were intraperitoneally injected.13, 14 Five days 
after the injection of HT1080 cells, the mice were utilized for imaging. 
 
2.2.8. In vivo and ex vivo fluorescence imaging 
The CB-CNP (100 μg/100 μl/mouse) was intravenously injected via the tail vein 
into all tumor-bearing mice. In vivo NIR tomographic images were acquired with an 
eXplore Optix system (Advanced Research Technologies Inc., Montreal, Canada). 
For quantitative analysis, the total photon counts in tumors were calculated using 
the region of interest (ROI) measurement of the Analysis Workstation software 
program (Advanced Research Technologies Inc.), and the tumor signal to 
background ratio (TBR) between the tumor and normal region was also evaluated as 
a function of time. In addition, in vivo NIR fluorescence was imaged with an IVIS 
Spectrum imaging system (Caliper Life Sciences, Hopkinton, MA). For in vivo 
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bioluminescence imaging, D-luciferin solution (150 mg/kg body weight) was 
intraperitoneally injected 10 min prior to imaging. Bioluminescence imaging was 
performed with the IVIS Spectrum imaging system. In vivo NIR fluorescence 
molecular tomography (FMT) system (VisEn Medical Inc., Bedford, MA) was 
operated with a 680 nm fluorescence channel to obtain three-dimensional (3-D) in 
vivo images of CB activity in the lung metastatic model. FMT images were acquired 
between 0.29 and 2.05 mm at 0.59-mm steps. FMT images were obtained by 
utilizing a continuous wave-type scanner to obtain transillumination, absorption, 
and reflectance data.  
After in vivo imaging studies, the mice were sacrificed, and the organs were 
excised and imaged using a Kodak image station (4000MM; Kodak, New Haven, 
CT) equipped with a special C-mount lens and Cy5.5 and RFP bandpass emission 
filters. In addition, ex vivo NIR fluorescence images of the organs were taken using 
the IVIS Spectrum imaging system. 
 
2.2.9. Histological and Western blot analyses 
Each organ was fixed in formalin (4%, v/v) and embedded in paraffin for 
hematoxylin and eosin (H&E) staining and IHC. Then, 5 m-thick sections cut from 
the paraffin-embedded specimens were stained with H&E. In addition, 5 m-thick 
sections were stained with the primary antibodies against CB. Signal visualization 
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was achieved with a Histostain®-Plus Kit. Sections were counterstained with 
Harris’s hematoxylin. Meanwhile, 8 m-thick frozen sections of HT29 
subcutaneous tumors were prepared for fluorescence microscopic imaging of Cy5.5 
and DAPI.  
For Western blot analysis, each aliquot of the extracted normal organ or metastasis 
mixed with a sample buffer (0.25 M of Tris, 0.8% [w/v] sodium dodecyl sulfate, 10% 
[v/v] glycerol, 0.05% [w/v] bromophenol blue, pH 6.8) was run on 7.5% 
polyacrylamide gel after boiling (10 min). Gels were transferred to a blot membrane 
using iBLOT (Invitrogen). Membranes were blocked with milk in Tris-buffered 
saline-Tween20 (TBST) at RT for 1 h and then incubated with anti-CB at RT for 1 h. 
Three washes (15 min each) with TBST were performed, and the membranes were 
incubated with a horseradish peroxidase-conjugated anti-mouse antibody for 30 min 
in TBST and then washed (three washes, 15 min each) with TBST. Immunoreactive 
proteins were visualized with enhanced chemiluminescence.  
 
2.2.10. Statistical analysis 
Data represents the means  standard deviation. A one-way analysis of variance 
was used for the comparison of variables between groups. A value of p < 0.05 was 




2.3.1. Development and characterization of cathepsin B-sensitive 
nanoprobe 
The CB-CNP was developed by conjugating CB-peptide probes (molecular weight 
2117 Da) which is composed of cathepsin B substrate peptide, NIR florophore 
(Cy5.5), and dark quencher (BHQ-3), on the surface of self-assembled CNPs as a 
carrier (Figure 2.2). CNPs were variously characterized.15-17 CNPs showed fast 
uptake into cancer cells because CNPs could avoid unintended uptake from 
macrophages and pass through vascular structure. Also, CNPs could enable efficient 
accumulation in tumor tissue likely due to in vitro/in vivo stability and rapid uptake 
into target tumor cells.9, 17 After these procedures, CB-peptide probe on CNPs could 
generate NIR fluorescence signals in response to CB. 
To develop CB-CNP, the peptide sequence, Gly-Arg-Arg-Gly-Lys-Gly-Gly with 
Arg-Arg as a recognition sequence was used.18 The Arg-Arg sequence is known to 
confer substantial specificity to cathepsin B as compared with other cathepsins.19, 20 
The CB-peptide probes were characterized by HPLC, UV/Vis spectra, fluorescence 
emission spectra, MALDI-TOF mass spectrometry, which indicated that CB-peptide 
probes were successfully developed (Figure 2.3). The CB-peptide probes were 
conjugated on the surface of CNPs in the presence of EDC and sulfo-NHS. The 
conjugation of CB-peptide probes to CNP was confirmed by measuring the 
absorption intensity of BHQ-3 (690 nm) using UV/Vis spectrophotometer (Figure 
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2.4). The absorption intensity of CB-CNP (0.8 μM) corresponds to 17 μM of CB-
peptide probe in the standard curve, indicating that approximately 21 molecules of 
CB-peptide probes were attached to 1 CNP molecule. Therefore, it was calculated 
that the molecular weight of CB-CNP was 345 kDa. TEM and DLS analyses 
showed that the CB-CNP formed a spherical nanoparticle and that it was 280 ± 24 
nm in diameter (Figure 2.5 a). The CB-CNP’s cytotoxicity in four different cell 
lines (HT29, 4T1-luc2, RFP-B16F10, and HT1080) was determined using CCK-8 
assay (Figure 2.5 b). The CB-CNP exhibited cell viability > 95% against all types of 
cells at concentrations up to 50 g/ml. 
The CB-CNP was significantly strongly quenched in physiological condition and 
specifically activated by CB. The CB-CNP’s fluorescence intensity was highly 
quenched in 25 mM of MES buffer at 37C. When the CB-CNP was incubated with 
various concentrations of CB for 50 min at 37C, the self-quenched CB-CNP’s 
fluorescence signal was activated (18, 11, 4.9, and 2.3-fold fluorescence increases 
for 8.0, 4.0, 2.0, and 1.0 nM of CB, respectively, for 50 min), depending on the CB 
concentrations (r2 = 0.99) (Figure 2.5 c). In particular, the CB-CNP boosted a 
considerable florescence signal with 1.0 nM of CB, demonstrating high sensitivity 
to active CB. The in vitro specificity of the CB-CNP was examined with CB, 
cathepsin D, cathepsin L, and CB plus inhibitor, respectively. During a 50-min 
incubation at 37C, the NIR fluorescent signal was time-dependently recovered 
when treated with CB, whereas minimal increases in fluorescence signals occurred 





























Figure 2.3. Analytical experiments including (a) HPLC, (b) UV/Vis spectra, (c) 
emission spectra, and (d) MALDI-TOF mass spectrometry of cathepsin B-peptide 
probe.  







































































Figure 2.4. Characterization of the cathepsin B (CB)-sensitive nanoprobe (CB-CNP) 
including (a) UV/Vis absorbance of CB-CNP (0.80 μM) and various concentrations 
of CB-peptide probes (2.5, 5.0, 10, 20 μM), (b) standard curve for calculation of the 
amounts of CB-peptide probes conjugated to chitosan nanoparticles (CNPs). 
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2.3.2. Advantages of nanoprobes for imaging of cathepsin B activity 
Advantages of nanoprobes for imaging of CB activity were confirmed in cellular 
condition and in vivo. An obvious intracellular fluorescence due to the activation of 
the probe after cellular uptake was detected after 60 min incubation with the CB-
CNP. The CB-CNP provided increasing Cy5.5 signal (red) in a time-dependent 
manner, whereas the fluorescence signals were not observed in cells incubated with 
cathepsin B inhibitor, indicating specific response of CB-CNP to CB (Figure 2.6). A 
more intense Cy5.5 signal with CB-CNP than that with CB-peptide probe was 
observed, which is attributed to fast uptake of CB-CNP into cancer cells. Fast 
uptake of the probe could be a critical factor for imaging of the pericellular protease 
such as cathepsin B.  
To validate the use of CB-CNP for in vivo imaging of CB, the whole-body 
fluorescence images were obtained in SCC7 tumor-bearing mice after intravenous 
injection of CB-CNP.19 An obvious fluorescence signal was detected from the 
tumor as early as 1 h after injection (Figure 2.7 a). The NIR fluorescence signal 
from the tumors were significantly increased to 6 h, and showed steady intense 
signals over 1 day post-injection of CB-CNP and CB-peptide probe. The NIR 
fluorescence signal from the tumor in CB-CNP-treated mouse slowly diminished 
after 1 day, but tumor tissue was still brighter than the surrounding normal tissue 
even after 2 days. Meanwhile, the NIR fluorescence signal from the inhibitor- 
treated tumors was significantly faint. The NIR fluorescence intensity in tumor 
tissue was also evaluated as a function of time after injection of CB-CNP, CB-
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peptide probe, and CB-CNP plus inhibitor to tumor-bearing mice, respectively 
(Figure 2.7 b). The signals gradually increased until 6 h after injection of CB-CNP 
and CB-peptide probe, whereas there was only a minimal increase in the inhibitor-
treated mice. At 6 h post-injection of CB-CNP and CB-peptide probe, the NIR 
fluorescence intensities in tumors were about 11.5 and 5.2 fold higher than that of 
the inhibitor-treated one. Highly enhanced signal of CB-CNP than that of CB-
peptide probe significantly demonstrated the advantage of tumor-targeting CNP 
carriers such as high accumulation in tumor tissue and fast uptake into tumor cells. 
To further assess the results of in vivo imaging, tumors and other organs were 
excised after whole body imaging at 6 h post-injection of probes, and examined 
using a Kodak Image Station.20 The highest NIR fluorescence intensity was 
markedly observed in the tumor of CB-CNP injected mouse, and ex vivo images of 
each group of mice were in accordance with the trends shown in the whole body 
imaging (Figure 2.7). 
 
2.3.3. Cellular uptake and cathepsin B distribution 
The CB-CNP’s cellular uptake and CB distribution were monitored in five 
different cell lines (Figure 2.8). In this study, the cancer cell lines HT29,21 4T1,22 
B16F10,23 and HT108024 which are known to highly express CB, were selected as 
positive target cell lines. As a negative control, NIH3T3 cell line was selected, as 
this cell line is known to have no or extremely low CB expression.25 In fact, CB was 
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cells, which suggested that the CB-CNP was internalized into tumor cells and 
activated in their cytoplasm. Conversely, only a faint Cy5.5 fluorescence was 
detected in NIH3T3 cells. In addition, the fluorescence signal from the CB-CNP 
(red) was co-localized with that of CB expression (green). These results clearly 
indicate that the CB-CNP could easily enter into tumor cells and specifically 
respond to CB in such cells.  
 
2.3.4. Probe specificity for cathepsin B in vivo 
The CB-CNP’s specificity for CB was evaluated in HT29 subcutaneous tumor-
bearing mice. Following systemic administration of the CB-CNP, the tumors’ NIR 
fluorescence signals significantly increased for 6 h and slowly diminished 
afterwards (Figure 2.9). In contrast, their NIR fluorescence signals were noticeably 
reduced when CB inhibitor was intratumorally injected 30 min before the CB-CNP 
administration. Six hours after the CB-CNP was intravenously injected, the NIR 
fluorescence intensity of non-treated tumors was 17.1 fold higher than that of 
inhibitor-treated tumors (27900 ± 4520 for non-treated tumors versus 1630 ± 363 
for inhibitor-treated tumors; p < 0.05). H&E displayed the growth of HT29 tumors, 
and IHC for anti-CB antibody showed substantial CB expression in the whole tumor 
tissue (Figure 2.9 c). Fluorescence microscopy images of non-treated tumors 
demonstrated significantly stronger Cy5.5 fluorescence than that of inhibitor-treated 
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without CB-sensitive moiety in the HT29 liver tumor model. Liver tumor model 
was induced by laparotomy and subsequent injection of HT29 tumor cells into the 
left lobe of the liver. In bright field images of the excised livers, the tumor region 
can be easily detected from normal regions due to its color change and mainly 
detected in the left lobe of the liver. Whereas the NIR fluorescence signal from 
CNP-Cy5.5 was widely detected throughout the left liver lobes including tumors, 
the signal from the CB-CNP was well localized to the tumor region in the left liver 
lobes (Figure 2.9 d).  
 
2.3.5. In vivo imaging of cathepsin B activity in three different metastatic 
mouse models 
Next, it was evaluated whether the CB-CNP could be used to discriminate 
metastases in three different metastatic mouse models. Liver metastasis model was 
induced by injecting 4T1-luc2 cells into spleen.10, 11 Metastases in the liver were 
detected in all mice 10 to 14 days after 4T1-luc2 cell injections into the spleen, as 
confirmed by bioluminescence imaging. Following systemic administration of the 
CB-CNP, strong NIR fluorescence signals were demonstrated in the vicinity of the 
liver and the spleen at 1 h, as measured in Optix (Figure 2.10 a). On the other hand, 
minimal fluorescence recovery was detected in normal mice after intravenously 
injecting the CB-CNP. Fluorescence signal from the CB-CNP was considerably 
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2.10b). Western blot analysis revealed that the level of CB expression in liver 
metastases had increased compared to normal liver (Figure 2.10 c). 
Lung metastases were induced in all animals 14 days after RFP-B16F10 cells 
expressing the RFP gene were injected into the tail vein. Following the systemic 
administration of the CB-CNP, the intense NIR fluorescence signal in the vicinity of 
the lungs was increasingly observed from 1 h to 12 h, as monitored by Optix 
(Figure 2.11 a). On the other hand, weak fluorescence recovery was detected in 
normal mice after the intravenous injection of the CB-CNP. Three-dimensional in 
vivo images of CB activity in lung metastases were acquired using VisEn FMT.26 
FMT technology is known to achieve several centimeters of tissue penetration.27, 28 
These images demonstrated variations in CB activity with position (between 0.29 
and 2.05 mm at 0.59-mm steps) (Figure 2.11 b). RFP signals expressed from 
excised lungs clearly indicated that metastases were induced in the lungs (Figure 
2.11 c). Also, ex vivo images of the lung metastasis revealed high accumulation and 
fluorescence activation of the CB-CNP by NIR fluorescence imaging. Conversely, 
minimal fluorescence was exhibited in ex vivo images of the normal lung. H&E 
displayed the growth of B16F10 tumors, which is different from that of normal 
lungs (Figure 2.11 d). Western blot analysis demonstrated that the level of CB 
expression in lung metastases had increased compared to normal lung (Figure 2.11 
e). 
Lastly, the CB-CNP’s potential for discriminating peritoneal metastases in vivo 
were investigated. Metastases in the peritoneum were induced in all animals 5 days 
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after HT1080 cells were intraperitoneally injected. Following the systemic 
administration of the CB-CNP, the NIR fluorescence signal around the peritoneal 
cavity was gradually enhanced from 1 h to 7 h, as measured by Optix (Figure 2.12 
a). Under in vivo observation using the IVIS system, substantial fluorescence 
activity around the peritoneal cavity of intact mice was also detected after the 
intravenous injection of the CB-CNP (Figure 2.12 b). In the ex vivo observation, 
several nodules with significant NIR fluorescence activity were detected on the 
peritoneum of the abdominal wall when CB-CNP was intravenously injected into 
the mice (Figure 2.12 c). H&E displayed the growth of HT1080 tumors, which is 
different from that of normal peritoneum (Figure 2.12 d). 
 
2.4. Discussion 
A significant amount of experimental evidence has been supported that CB takes 
part in the metastatic process: a number of studies have obviously demonstrated that 
CB activity is closely correlated with tumors’ invasive and metastatic potential.29-31 
Many studies have implicated elevated CB activity in the metastatic process in vitro. 
However, few studies have demonstrated visualization of CB activity in the 
metastases in vivo, as unsatisfactory sensitivity make it difficult to detect metastases 
in host tissues, and in vivo metastatic mouse model that closely mimics the clinical 
situation lacks.32 In this study, a CB-sensitive and tumor-targeting fluorescence 
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its potential use for discriminating metastases in vivo. 
CB-CNPs can be used to improve the detection of metastases compared to CNP- 
Cy5.5. Remarkably, the CB-CNP, consisting of CB-responsive probes conjugated 
onto the surface of tumor-targeting CNP, allowed the tumor tissue to be clearly 
distinguished from the surrounding normal tissue in a liver tumor model (Figure 2.9 
d). The CNP-Cy5.5 mainly accumulated in the tumor tissue rather than the normal 
liver tissue.9 This is attributed to superior tumor-targeting ability and cell 
permeability of CNPs.9, 33 The CB-CNP’s ability to discriminate between tumor 
tissue and normal tissue more distinctly can be explained in two steps. First, the 
CB-CNP can be preferentially accumulated in tumor tissues instead of normal tissue 
via enhanced permeability and retention effects in the same manner as CNP-Cy5.5. 
Additionally, the CB-CNP undergoes a selective enzymatic cleavage due to the 
elevated CB activity in metastatic tumor tissues.  
Fluorescence imaging using the CB-CNP can provide high sensitivity to detect 
metastases in cellular and in vivo systems because it can stay strongly self-quenched 
in normal tissue. A high level of sensitivity is required to successfully image 
disseminated metastases. In terms of sensitivity, an activatable imaging system 
using the fluorophore (Cy5.5)-quencher (BHQ-3) pair is favorable.34 Fluorescence 
imaging is able to distinguish target tumors, taking the surrounding background as a 
reference.35 Therefore, it is significant to enhance the signal in tumor cells or tissues 
while reducing the signal in background normal cells or tissues. Due to the effective 
fluorescence-quenching property of the quencher (BHQ-3) and the self-quenching 
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of the fluorophores (Cy5.5), this activatable peptide probes which were covalently 
onto the surface of the self-assembled nanoparticles, produced a low fluorescence 
signal in the quenched state. This contributed to extremely low background noise. 
Moreover, the fluorescence signal of this system was remarkably boosted by the 
target enzyme (CB), contributing greatly to sensitive detection. Thus, the activatable 
system using a well-matched fluorophore-quencher pair can improve sensitivity, 
enabling the sensitive and early in vivo diagnosis of metastases.  
There are available in vivo metastatic mouse models.36 Intrasplenic injections of 
4T1 cells have established liver metastases as well as primary intrasplenic tumors.10 
Dissemination of metastatic cells from splenic tumors into the liver has been carried 
out by the portal system.37 In particular, 4T1 cells are known to show strong 
potential for tumor invasion and metastasis.38, 39 In fact, 4T1-luc2 cells injected into 
the spleen have effectively developed metastases in many other organs as well as 
liver, which is easily confirmed by luminescence imaging due to the transfected 
luc2 gene (Figure 2.10). Therefore, fluorescence signal in living mice was detected 
in primary tumor of spleen and other metastases as well as liver metastases. 
Pulmonary metastases developed by injecting B16 melanoma cells into the tail vein 
are the best characterized among the experimental metastasis models.40, 41 In the 
present study, lung metastases induced with RFP-B16F10 cells were clearly 
confirmed by RFP signals ex vivo (Figure 2.11 c). Peritoneal metastases developed 
by intraperitoneally injecting HT1080 cells have been used in many metastasis 
studies.13, 14, 42 In addition, HT1080 cells are known as highly malignant cells.42, 43 
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Metastases in the peritoneum were confirmed by observable differences from 
normal peritoneum in H&E staining (Figure 2.12 d). These metastatic mouse 
models have several advantages for research.36 Many of these models are consistent 
and reproducible. The type and number of injected cells can be controlled. Indeed, 
three metastases used in the study were induced in all animals in which tumor cells 
were injected. In addition, the time course required for model maturity is relatively 
rapid in these models. However, these models are pathophysiologically far from 
naturally occurring metastases and only partially resemble the relevant clinical 
situation in the metastatic process.44 Therefore, in vivo models of metastases that 
more closely mimic the clinical situation are needed for clinical cancer research.  
An increasing number of treatments of metastases rely on diagnostics and imaging 
these days. Decisions for cancer patients’ treatment are based on detecting and 
imaging the extent of the disease’s spread. In addition, several treatments including 
directed radiotherapy require the exact tumor localization to be known. Being able 
to non-invasively visualize gross metastases and metastatic cell clusters within the 
intact whole body could help to facilitate guided surgery. Having the ability to 
accurately localize metastases during surgery is helpful for surgeons to eradicate 
metastases when using fluorescence cameras in the operating room. Fluorescence 
imaging using the CB-CNP developed in this study could be utilized as a means for 
guided surgery. The CB-CNP can be quite practical because it enables the fast and 
easy acquisition of images, which is advantageous for avoiding associated health 
risks by minimizing time under anesthesia.10 
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2.5. Conclusions 
The facts that the activity of CB is markedly linked to the metastatic process and 
that CB is found highly expressed in the pericellular regions in this process make 
CB an attractive target for diagnosing metastases. The CB-CNP consisting of CB-
sensitive fluorescence peptide probes conjugated onto the surface of tumor-targeting 
glycol chitosan nanoparticles, facilitated specific and sensitive visualization of CB 
activity in the cellular study and in vivo tumor models. Importantly, the CB-CNP 
demonstrated the potential to discriminate metastases in vivo in three metastatic 
mouse models including liver, lung, and peritoneal metastases. Developing a 
molecular imaging technology to depict metastases enables medical therapy to be 
personalized, tailoring treatment to each individual patient by minimizing the risks 
and maximizing the benefits.  
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 Epidermal growth factor receptor-






Receptor-targeted imaging is emerging as a promising strategy for the diagnosis of 
human cancer.1, 2 The advantage of specific receptor targeting is obvious - the use of 
imaging probes with higher specificity towards the target receptor allows highly 
sensitive and selective imaging with a low dose of the probe.3-5 Furthermore, 
receptor-targeted imaging could be helpful in selecting patients for receptor-targeted 
therapy before the course of treatment.4 During treatment, receptor-targeted imaging 
can also monitor effects of the receptor-targeted therapy, allowing clinicians to 
identify tumor responsiveness before evaluation of traditional, late-stage markers of 
treatment efficacy, such as a change in tumor size. 
Epidermal growth factor receptor (EGFR) is an important target receptor in many 
types of cancers, including non-small cell lung cancer, skin cancer, breast cancer, 
small cell carcinoma of head and neck, and prostate cancer.6-8 Overexpression of 
EGFR is shown to be correlated with poor prognosis and increased metastatic 
potential.9,10 The current standard method to image EGFR has utilized EGFR 
antibodies, due to their exquisite specificity towards EGFR in tumor cells. When 
modified with radioisotopes or magnetic or fluorescent probes, EGFR antibodies are 
used to image various tumors by nuclear, magnetic resonance (MRI), and 
fluorescence imaging, respectively.11-13 However, despite numerous studies using 
EGFR antibody-based imaging probes, they are still limited and insufficient, due to 
the big size of EGFR antibodies (150 kDa) that cause some drawbacks in receptor-
69 
targeted imaging, such as long circulation time, poor tissue permeability, and slow 
clearance from the body (few days to weeks), etc.14,15 
Recently, epidermal growth factor (EGF) has shown great potential for EGFR-
targeted cancer imaging.16-18 EGF is the natural ligand for EGFR and is comprised 
of 53 amino acids with a molecular weight of ~6 kDa. EGF offers unique 
advantages for targeting EGFR over EGFR antibody: the binding affinity is 
typically stronger, cell penetration occurs in deeper regions of the tumor, and 
clearance rates are more rapid because of a smaller molecular weight compared to 
EGFR antibody.19,20 For targeted EGFR imaging, EGF molecules have been labeled 
with various radionuclides and organic dyes for cell and small animal imaging.11-13 
Owing to its small size and high affinities, EGF-based imaging probe generally 
show fast tumor targeting (within a half hour), high tumor uptake, and quick 
clearance from normal tissues.16 Therefore, EGF-based probes have been known to 
be a good platform for developing imaging probes for EGFR.  
Herein, for construction of an EGFR-specific and activatable probe, EGF was 
labeled with a quencher and a near-infrared (NIR) fluorophore, producing a 
fluorescently quenched EGF-based nanoprobe (EGF-NP) (Figure 3.1). A 
fluorescently quenched imaging probe can reduce background signals and boost 
strong fluorescence intensity, as in the case of EGF-NP for targeted EGFR imaging. 
Various protease-targeted activatable nanoprobes were developed for in vivo 
fluorescence imaging, which have a strongly dual-quenched (dye-dark quencher and 
dye-dye self-quenching mechanism) system.21-25 They showed highly efficient 
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quenching and responsive amplified fluorescent signals upon exposure of the probes 
to targeted protease in vitro and in vivo. 
EGF-NP can be intensely activated in high EGFR-expressing cells and high 
EGFR-expressing tumor-bearing mice, compared to low EGFR-expressing cells and 
low EGFR-expressing tumor-bearing mice. Cellular imaging of EGF-NP in tumor 
cells was captured using live cell imaging microscopy with a video imaging system. 
In addition, cellular imaging and whole body imaging of EGF-NP treatment was 
compared to EGFR antibody (Cetuximab)-Cy5.5 conjugates. 
 
3.2. Experimental section 
3.2.1. Materials 
EGF consisting of 53 amino acid with a molecular weight of 6215 Da was 
obtained from Sigma (St. Louis, MO). Cy5.5 N-hydroxysuccinimide (NHS) ester 
(Cy5.5-NHS; excitation/emission: 675/695 nm) was purchased from GE Healthcare 
(Piscataway, NJ) and black hole quencher 3 NHS ester (BHQ3-NHS; maximum 
absorbance: 650 nm) was from Biosearch Technologies, Inc. (Novato, CA). PD-10 
disposable columns and gradient gel were purchased from Amersham Pharmacia 
Biotech (Uppsala, Sweden) and Elpisbio (Taejeon, Korea), respectively. EGFR 
antibody was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA) and 







































































































(Milford, MA). Lipofectamine was purchased from Invitrogen (Carlsbad, CA). 
DMEM and RPMI 1640 were purchased from Gibco (Grand Island, NY). Cell 
Counting Kit-8 (CCK-8) and a human EGF enzyme-linked immunosorbent assay 
(ELISA) kit were purchased from Dojindo Molecular Technologies, Inc. 
(Kumamoto, Japan) and RayBiotech, Inc. (Norcross, GA), respectively. 
 
3.2.2. Synthesis and characterization of epidermal growth factor-based 
nanoprobe 
An aqueous solution of recombinant human EGF (0.32 μmol, 1 ml sodium 
bicarbonate buffer, 0.1 M, pH 9.5) was incubated with Cy5.5-NHS (0.32 μmol) in 
500 μl dimethyl sulfoxide (DMSO) at room temperature (RT) for 30 min. Then, 
BHQ3-NHS (0.32 μmol) in 500 μl DMSO was added to the aqueous solution of 
EGF-Cy5.5, which was reacted at RT for 30 min. The reaction mixture was purified 
with preparative reverse phase-high performance liquid chromatography (RP-
HPLC); 20% to 80% acetonitrile containing 0.1% trifluoroacetic acid (TFA) versus 
distilled water containing 0.1% TFA over 40 min at a flow rate of 1.0 ml/min. The 
collected fractions, EGF-Cy5.5-BHQ3 conjugates (EGF-NP), were stored at 4°C for 
further use.  
EGF-NP was characterized using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), spectrofluorometry, analytical RP-HPLC equipped 
with a ZORBAX 300SB-C18 column, and matrix-assisted laser 
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desorption/ionization-time of flight (MALDI-TOF). For SDS-PAGE, EGF, EGF-
Cy5.5 and EGF-NP were mixed with an equal volume of sample buffer (0.25 M Tris 
[pH 6.8] containing 0.1% [w/v] bromphenol blue), respectively. The mixed products 
were loaded on a 15% gradient polyacrylamide gel. The gel was washed twice with 
2.5% (v/v) Triton X-100 solution (30 min and 1 h each) and incubated in 50 mM 
Tris HCl (pH 7.5), 10 mM CaCl2 and 0.2 M NaCl at 37°C for 24 h. The gel was 
stained with 3% (w/v) Coomassie blue, dried and scanned. Fluorescence signal of 
gels was imaged using a Kodak Image Station (4000 MM; Kodak, New Haven, CT). 
Kodak Image Station is equipped with the excitation filter for Cy5.5 and halogen 
lamp. Fluorescence images were obtained with an emission filter (680 to 720 nm; 
Omega Optical, Brattleboro, VT) and 12-bit CCD camera equipped with C-mount 
lens. In addition, fluorescence intensities of EGF-Cy5.5 and EGF-NP were 
measured using a fluorescence spectrophotometer (F-7000, Hitach, Tokyo, Japan). 
MALDI-TOF mass spectrometry was used to measure the molecular weight of EGF, 
EGF-Cy5.5 and EGF-NP using a MALDI-TOF system (Microflex LRF20, Bruker 
Daltonics, Bremen, Germany). Cy5.5, EGF, EGF-Cy5.5 and EGF-NP were 
characterized by analytical RP-HPLC; 5% to 90% acetonitrile containing 0.1% TFA 
versus distilled water containing 0.1% TFA over 20 min at a flow rate of 1.0 ml/min. 
To evaluate the de-quenching ability, EGF-NP was incubated in phosphate-buffered 
saline (PBS, pH 5.0) with or without lysozyme and 5% sodium dodecyl sulfate 
(SDS) for 20 min, and then imaged with Kodak Image Station. As control, EGFR 
monoclonal antibody, Cetuximab (3.3 nmol) was incubated with Cy5.5-NHS (40 
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nmol) in 0.1 M Na2HPO4 (pH 8.5) at RT for 1.5 h. Then, the reaction mixture was 
purified with a PD-10 column to remove unbound Cy5.5.  
 
3.2.3. Cytotoxicity 
Human breast cancer cell lines, MDA-MB-468 (high EGFR-expressing) and 
MDA-MB-436 cells (low EGFR-expressing) were obtained from the American 
Type Culture Collection (Manassas, VA).26 MDA-MB-468 cells were cultured in 
DMEM containing 10% fetal bovine serum (FBS) and 100 U/ml penicillin and 
MDA-MB-436 cells were cultured in RPMI 1640 containing 10% FBS and 100 
U/ml penicillin. Cytotoxicity was evaluated using CCK-8. In brief, MDA-MB-468 
cells and MDA-MB-436 cells, respectively, were seeded in a 96-well microplate 
and incubated with various concentrations of the EGF-NP (0 to 50 μg/ml) for 24 h 
before incubation with CCK-8 solution for 2 h. Absorbance was measured at 450 
nm with a plate reader. Cell viability was calculated as the percentage of viable cells 
relative to untreated cells. 
 
3.2.4. Binding studies 
The binding assay was performed in a 96-well microplate coated with anti-human 
EGF antibody from a human EGF ELISA kit. One hundred microliters of 
unmodified human EGF and EGF-NP were incubated for 2.5 h at RT, allowing 
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binding to the coated antibody. After discarding the solution and washing with wash 
buffer, biotinylated anti-human EGF antibody (100 μl) was incubated in the wells 
for 1 h at RT. After washing with wash buffer, horseradish peroxidase-conjugated 
streptavidin (100 μl) was incubated in the well for 45 min at RT. After washing with 
wash buffer, 3,3’,5,5’-tetramethylbenzidine One-Step Substrate Reagent (100 μl) 
was incubated for 30 min at RT in the dark. Stop Solution was added to each well, 
and the absorbance of the solution was measured at 450 nm.  
To directly assess EGFR binding, MDA-MB-468 or MDA-MB-436 cells (1×105 
cells/dish) were plated in 35 mm coverslip bottom dishes and then incubated 
overnight. EGF-NP (10 μM) was added into each well and then incubated for 6 h. 
For the blocking test, EGFR monoclonal antibody, Cetuximab (4.0 μM) was treated 
to the culture medium 72 h before EGF-NP treatment. For in vitro EGFR siRNA 
silencing, EGFR siRNA and lipofectamine 2000 were mixed for 20 min in 100 μl 
PBS, and then the cells were treated with siRNA-lipofectamine complexes (10 nM) 
for 72 h. Microscopy was performed on a Deltavision system (Applied Precision, 
Issaquah, WA). The sample was imaged using a microscope (IL-70, Olympus, 
Tokyo, Japan) equipped with a mercury arc lamp. Differential visualization of the 
fluorophores was achieved with 660 nm/710 nm, 360 nm/457 nm, 490 nm/528 nm 
filters (excitation/emission).  Images were analyzed with the SoftWorRx program 
from Applied Precision.  
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3.2.5. Cellular imaging 
MDA-MB-468 cells (1×105 cells/dish) were plated in 35 mm coverslip bottom 
dishes and cultured for 36 h, respectively. After washing with PBS (pH 7.4), the 
cells were incubated in serum-free medium containing EGF-NP (10 μg/ml) for 0, 4 
or 8 h. The cells were fixed in methanol and incubated with Alexa Fluor® 488-
conjugated anti-EGFR for EGFR staining, Alexa Fluor® 405-conjugated anti-
LAMP-1 for lysosomal marker, or 4′,6′-diamidino-2-phenylindole hydrochloride 
(DAPI) for nuclear staining at RT for 10 min. Cells were observed on a Deltavision 
system. To visualize live cell imaging, MDA-MB-468 cells on a 35 mm coverslip 
bottom dishes were placed in a CO2- and temperature-controlled chamber of a 
microscope. Images were captured at 5 min intervals over 90 min with a cooled 
charged-coupled device video camera (CoolSNAP fx CCD camera, Photometrics, 
Tucson, AZ). Cells were exposed for 100 ms and 5000 ms to acquire differential 
interference contrast (DIC) images and NIR fluorescence images, respectively. To 
collect cell images before and after the washing process, MDA-MB-468 cells in 35 
mm coverslip bottom dishes were incubated with EGF-NP or Cetuximab-Cy5.5 for 
2 h. Cell image was captured with IX81-ZDC focus drift compensating microscope 
(Olympus, Tokyo, Japan) equipped with a 673-nm excitation filter and a 692-nm 
emission filter. Then, these cells were washed twice with PBS (pH 7.4) and 
visualized with the same equipment. 
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3.2.6. In vivo and ex vivo fluorescence imaging 
All animal experimental procedures were in compliance with the institutional 
guidelines of Korea Institute of Science and Technology and the relevant laws. 
MDA-MB-468 and MDA-MB-436 cells (1  107 cells/mouse) suspended in PBS 
(100 l) were subcutaneously injected into the left flank and right flank of athymic 
nude mice (20 g, Institute of Medical Science, Tokyo), respectively. For in vivo 
EGFR siRNA silencing, MDA-MB-468 (1  107 cells/mouse) suspended in PBS 
(100 l) were subcutaneously injected into both the left and right flanks of athymic 
nude mice.  When tumors reached a size of approximately 5 mm in diameter, EGF-
NP (100 g/100 l PBS/mouse) was intravenously injected via a tail vein into the 
mice either directly or following pretreatment with siRNA complex. EGFR siRNA 
and lipofectamine 2000 were mixed for 20 min in 100 μl PBS, and then EGFR 
siRNA-lipofectamine complexes were intratumorally injected into the MDA-MB-
468 tumor in the right flank 1 day before intravenous EGF-NP injection. For 
comparison study of in vivo biodistribution and tumor accumulation of EGF-NP and 
Cetuximab-Cy5.5, EGF-NP (300 g/100 l PBS/mouse) and Cetuximab-Cy5.5 (300 
g/100 l PBS/mouse) were intravenously injected via the tail vein into the mice. In 
vivo NIR fluorescence tomographic images were acquired with an eXplore Optix 
system (ART Advanced Research Technologies Inc., Montreal, Canada).27 Imaging 
was performed at a predetermined post-injection time point and the total 
fluorescence intensity in tumor was calculated with the region of interest analysis of 
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Analysis Workstation software (ART Advanced Research Technologies Inc.). For ex 
vivo NIR fluorescence imaging, tumors were excised and imaged with a Kodak 
Image Station at 3 h post-injection of EGF-NP. 
 
3.2.7. Histological and Western blot analyses 
Three hours after probe injection, each excised tumor was divided into 2 pieces. 
One was fixed in 4% (v/v) buffered formalin and then embedded in paraffin for 
hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC). The other 
was embedded in optimal cutting temperature compound for cryo-section 
preparation and further fluorescence microscopic imaging. The paraffin-embedded 
specimens were cut into 5 m-thick sections and stained with H&E. For 
immunohistochemical analyses, 5 m-thick sections were stained with primary 
antibodies against EGFR. The staining signals were developed with a Histostain®-
Plus Kit (Invitrogen). Harris’s hematoxylin was used for counterstaining. The 8 m-
thick frozen sections were prepared for fluorescence microscopic imaging of Cy5.5 
and DAPI. The sections were observed under the microscope without any 
histological stains. 
Cell extract was clarified by centrifugation at 4°C (15000 g, 10 min). The cells 
were resuspended in cold lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% 
Nonidet P-40) containing protease inhibitor cocktail for 30 min. Protein extracts 
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were clarified by centrifugation at 4°C (15000 g, 30 min). Protein extracts were 
loaded onto SDS-PAGE, and gels were then transferred to a nitrocellulose 
membrane using an iBLOT system (Invitrogen, Carlsbad, CA). The membrane was 
blocked with 5% milk in Tris buffered saline with Tween 20 (TBST) at RT for 1 h 
and then incubated with primary antibody (EGFR antibody) at RT for 1 h. The 
membrane was washed three times (15 min each) and then incubated with 
horseradish peroxidase-conjugated anti-mouse antibody in TBST for 30 min. 
Immunoreactivity was visualized using enhanced chemiluminescence. 
 
3.2.8. Statistical analysis  
Values are expressed as means ± standard deviation. A one-way analysis of 
variance (ANOVA) was used for the comparison of continuous variables between 
groups. P < 0.05 was considered statistically significant. 
 
3.3. Results  
3.3.1. Preparation of epidermal growth factor-based nanoprobe 
The EGF-NP was developed by a two-step conjugation of Cy5.5 and BHQ3 onto 
EGF. The procedure of EGF-NP synthesis was monitored by HPLC, mass 
spectroscopy and SDS-PAGE. Each EGF has three amine groups (N-terminal and 2 
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lysine) available for reaction with Cy5.5-NHS or BHQ3-NHS. As seen in the crystal 
structure of EGF-NP (Figure 3.1 a), three amine groups are exposed on the surface 
of EGF, allowing easy conjugation with Cy5.5-NHS or BHQ3-NHS. After a two-
conjugation process with Cy5.5-NHS or BHQ3-NHS, the resulting product was 
purified from unbound fluorophores using a PD-10 column. HPLC results of 
purified EGF-NP demonstrated successful elimination of unbound Cy5.5 or BHQ3 
(Figure 3.2). Mass spectrometry showed a peak at 7270 Da in EGF-Cy5.5 and at 
8184 Da in EGF-NP, respectively, indicating that approximately 1 molecule of 
Cy5.5 and 1 molecule of BHQ3 were attached to 1 EGF molecule in the EGF-NP 
(Figure 3.3 a). SDS-PAGE showed that Cy5.5 and BHQ3 were covalently 
conjugated to the EGF molecules in the EGF-Cy5.5 and EGF-NP groups (Figure 3.3 
b). With the same Cy5.5 concentration, EGF-NP was found to have a quenched 
fluorescence effect in PBS compared to EGF-Cy5.5 (Figure 3.3 c). 
 
3.3.2. Characterization and cellular imaging of epidermal growth factor-
based nanoprobe 
Fluorescence recovery of EGF-NP was evaluated by adding lysozyme, one of the 
proteolytic enzymes found in lysosomes, and 5% SDS. EGF-NP was well dispersed 
and quenched in the PBS (Figure 3.4 a). After exposure to lysozyme and SDS for 20 
min in RT, the fluorescence intensity of EGF-NP increased 3.5 ± 0.6 fold (Figure 




Figure 3.2. HPLC profiles of (a) Cy5.5, (b) epidermal growth factor (EGF)-Cy5.5, 
(c) EGF, (d) epidermal growth factor-based nanoprobe (EGF-NP). The signal is 
detected at 280 nm. 

















































































































































fluorescence recovery after internalization and lysosomal degradation of EGF-NP. 
To evaluate the cytotoxic effect of EGF-NP in high (MDA-MB-468) or low EGFR-
expressing cells (MDA-MB-436), a cell viability assay was performed using CCK-8 
solution. EGF-NP exhibited cell viability > 95% against MDA-MB-468 cells at 
concentrations lower than 10 g/ml and against MDA-MB-436 cells at 
concentrations up to 50 g/ml (Figure 3.4).  
In this study, MDA-MB-436 cells and MDA-MB-468 cells were used as low 
EGFR-expressing cells and high EGFR-expressing cells, respectively. When EGF-
NP were treated, fluorescence seen in MDA-MB-468 cells was stronger than that in 
MDA-MB-436 cells (Figure 3.5 a). Tumor cells were monitored using live cell 
imaging microscopy as time passed. MDA-MB-468 cells showed gradually 
increasing NIR fluorescence depending on the EGF-NP incubation time, enabling 
clear visualization of the probe activation process in cells (Figure 3.5 b).  
Upon EGF-NP treatment, MDA-MB-468 cells exhibited a low background 
fluorescence signal without washing (Figure 3.5 c). Of course, EGF-NP provides a 
higher contrast image after washing with buffer, compared to that before washing. 
EGFR monoclonal antibody, Cetuximab conjugated with Cy5.5 (Cetuximab-Cy5.5) 
also produced a strong fluorescence signal in cells following washing. However, 
cells without the washing process produced a high background fluorescence signal. 
The low background signals caused after EGF-NP treatment allow real-time 









































sity of (a). I
























3.3.3. Probe specificity for epidermal growth factor receptor 
EGF-NP has affinity and specificity required for imaging cellular EGFR. Three 
amine groups in each EGF can be conjugated with Cy5.5 or BHQ3, but can also 
deteriorate EGF capacity to bind to EGFR. Therefore, ELISA-based binding assay 
for anti-human EGF antibody was performed with various concentrations of 
unmodified EGF and EGF-NP (0.8 to 200 pg/ml) (Figure 3.6).19 Compared to 
unmodified EGF, EGF-NP showed lower binding affinity for anti-EGF antibody. 
However, EGF-NP exhibited comparable binding affinity for anti-EGF antibody, 
which means that the fluorophore conjugation process onto EGF does not 
substantially deteriorate the capacity of EGF-NP to bind to EGFR. However, this 
assay does not directly measure EGFR binding. To further evaluate EGFR-binding 
affinity of EGF-NP directly, cellular binding studies were done in MDA-MB-468 
cells. Pretreatment of Cetuximab, EGFR monoclonal antibody, to MDA-MB-468 
cells importantly blocks binding of ligand, resulting in significantly reduced cellular 
fluorescence.  
 
3.3.4. Intracellular location of activated epidermal growth factor-based 
nanoprobe 
EGF-NP is importantly activated in the lysosome of the cells. EGF-NP showed 
fluorescence signals in the cytoplasm 4 h after probe treatment in MDA-MB-468 
cells, whereas EGF-Cy5.5 conjugate exhibited fluorescent signals at the cell surface 
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fluorescent recovery of EGF-NP occurs in cell’s lysosome, the cells were incubated 
with LAMP-1 (a lysosomal marker). The fluorescence dots from EGF-NP well-
matched with LAMP-1 fluorescence signals, suggesting that lysosomal degradation 
causes the fluorescence recovery of EGF-NP.  
 
3.3.5. In vivo fluorescence imaging in tumor-bearing mice 
Intravenous injection of EGF-NP into tumor-bearing mice induced higher NIR 
fluorescence intensity in high EGFR-expressing tumors than in low EGFR-
expressing tumors. After intravenous injection of EGF-NP into tumor-bearing mice, 
a strong fluorescence signal was detected from MDA-MB-468 tumors on the left 
flank as early as 30 min, and diminished after 1 h (Figure 3.7 a). Meanwhile, the 
NIR fluorescence signal from MDA-MB-436 tumors on the right flank of the mice 
was relatively faint, compared to that of MDA-MB-468 tumors on the left flank. To 
further assess the results of in vivo imaging, tumors were excised 3 h post-injection 
of EGF-NP. In the NIR ex vivo image, MDA-MB-468 tumor exhibited a stronger 
fluorescence signal, compared to the MDA-MB-436 tumor (Figure 3.7 b). Distinct 
fluorescence signals appeared from high EGFR-expressing tumor as early as 30 min 
after intravenous injection of EGF-NP, which indicates that this system can be a 
rapid cancer detection method.  
Intravenous injection of EGF-NP into tumor-bearing mice induced higher NIR 





Figure 3.6. Binding assay showing the affinity of unmodified human epidermal 


























expressing tumors. After intravenous injection of EGF-NP into tumor-bearing mice, 
a strong fluorescence signal was detected from MDA-MB-468 tumors on the left 
flank as early as 30 min, and diminished after 1 h (Figure 3.7 a). Meanwhile, the 
NIR fluorescence signal from MDA-MB-436 tumors on the right flank of the mice 
was relatively faint, compared to that of MDA-MB-468 tumors on the left flank. To 
further assess the results of in vivo imaging, tumors were excised 3 h post-injection 
of EGF-NP. In the NIR ex vivo image, MDA-MB-468 tumor exhibited a stronger 
fluorescence signal, compared to the MDA-MB-436 tumor (Figure 3.7 b). Distinct 
fluorescence signals appeared from high EGFR-expressing tumor as early as 30 min 
after intravenous injection of EGF-NP, which indicates that this system can be a 
rapid cancer detection method. 
Furthermore, administration of EGFR siRNA lowered the fluorescence intensity 
of EGF-NP in MDA-MB-468 tumors (Figure 3.8). EGFR siRNA was intratumorally 
injected into the tumor on the right flank 1 day before EGF-NP administration. 
Fluorescence intensity in non-treated tumors on the left flank was significantly 
higher (p < 0.05) than that in siRNA-treated tumors on the right flank of the mice at 
1, 3 and 6 h after EGF-NP treatment. To further evaluate the findings from in vivo 
images, the extracted tumors were examined with a Kodak Image Station and by 
histology. Higher NIR fluorescence intensity was clearly observed in non-treated 
extracted tumors over siRNA-treated extracted tumors, which was consistent with in 
vivo optical imaging. Tumor sections were also analyzed by histology and 
fluorescence microscopy. H&E staining demonstrated similar carcinoma growth in 
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both non-treated and siRNA-treated tumors. IHC for EGFR antibody showed strong 
EGFR expression in non-treated tumors and significant EGFR gene silencing in 
siRNA-treated tumors. Fluorescence images also demonstrated that Cy5.5 
fluorescence of EGF-NP from non-treated tumor tissues was significantly higher 
than that from siRNA-treated tumor tissues. 
Signal accumulation of EGF-NP in EGFR expressing tumors was much faster than 
that of the Food and Drug Administration (FDA)-approved EGFR monoclonal 
antibodies conjugated with the same NIR fluorophore (Cy5.5). FDA-approved 
monoclonal antibodies conjugated with NIR fluorophores have been used as 
imaging agents.28,29 Therefore, EGFR antibody and EGF-NP conjugated with the 
same NIR fluorophore were compared as imaging agents by in vivo distribution and 
tumor accumulation. First, Cetuximab-Cy5.5 conjugates and EGF-NP were 
intravenously injected into the tail vein of MDA-MB-468 tumor-bearing mice, 
respectively. After administration of both agents, fluorescent signal in tumors 
increased over time (Figure 3.9 a). The EGF-NP signal in the tumor peaked within 
the first 12 h of the measurement, whereas the Cetuximab-Cy5.5 signal slowly 
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For EGFR-targeted fluorescently activatable imaging, it was hypothesized that 1) 
the fluorescence of EGF when labeled with a NIR fluorophore and a quencher 
would be strongly quenched when outside the target cells, 2) binding to EGFR 
would lead to cellular internalization and intracellular degradation of EGF-NP in the 
lysosome, and 3) lysosomal degradation of EGF-NP would cause separation of the 
fluorophore from the quencher, allowing a recovered, strong fluorescence signal 
only within the EGFR-positive cells (Figure 3.1). This newly designed EGF-NP is 
hypothesized to have strongly quenched fluorescence in the blood stream, via the 
quenching effect between dyes and quenchers, but after cellular internalization and 
lysosomal degradation the quenched EGF-NP can boost strong NIR fluorescence 
intensity. 
Optical imaging probes are used to distinguish the target tumor by taking the 
surrounding background as a reference.30 Therefore, it is important to increase the 
signal in the target tumor cells or tissues while decreasing the signal in the 
surrounding background to improve the efficiency of these probes. An activatable 
system using the fluorophore-quencher pair emits low to no fluorescence signal in 
the quenched state, because the emitting light from the fluorophore is absorbed by 
the quencher via fluorescence resonance energy transfer (FRET).31 This 
fluorescence activatable effect is an important contribution to the optical probe, 
because it keeps background signals low, while displaying fluorescent signals in the 
target cells, thereby resulting in sensitive detection. 
The mechanism of fluorescent recovery of activatable EGF-NP involves a series 
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of events; EGFR binding, cellular internalization, and lysosomal degradation. 
EGFR-EGF complex is usually internalized and undergoes degradation by 
lysosomal proteases in the lysosome after EGF binds to the EGFR.32,33 Similar to 
EGF-EGFR complex, EGF-NP is hypothesized to bind to EGF receptor, be 
internalized, and be degraded in the cellular lysosome. In the present study, EGF-NP 
obviously showed the capability to bind to the EGFR. Moreover, NIR fluorescence 
signal of EGF-NP was recovered in the presence of lysozyme, one of the proteases 
found in lysosomes, and SDS, (Figure 3.4), and fluorescence dots from EGF-NP in 
cellular imaging matched with lysosomal marker fluorescence signals. Developing 
an imaging probe monitoring the mechanism can help to pinpoint the source 
causing the cancer of specific patients.  
EGF-NP specifically targets EGFR-positive tumor cells. A more intense 
fluorescent intracellular signal was observed in MDA-MB-468 cells than in MDA-
MB-436 cells after EGF-NP treatment (Figure 3.5). Furthermore, EGFR siRNA 
pretreatment in high EGFR-expressing MDA-MB-468 cells resulted in specific 
knockdown of the EGFR gene and subsequent decrease of fluorescent signal from 
EGF-NP. This supports that fluorescence recovery of EGF-NP is likely due to 
specific binding of EGF-NP to EGFR and internalization into EGFR-positive cells. 
In vivo specific targeting of EGF-NP to EGFR-positive tumor cells was 
demonstrated by higher NIR fluorescence intensity in high EGFR-expressing 
tumors over low EGFR-expressing tumors (Figure 3.7). In addition, NIR 
fluorescence signal from siRNA-treated MDA-MB-468 tumors was significantly 
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lowered compared to that of non-treated MDA-MB-468 tumor (Figure 3.8). 
Therefore, both in vitro cellular imaging and in vivo optical imaging support that 
EGF-NP specifically targets EGFR-positive tumor cells. 
In addition, EGF-NP was also cleared more quickly from the body compared to 
Cetuximab-Cy5.5. In literature, two different radiolabelled imaging agents, EGF 
(Mr, 6 kDa) labeled with 111In (EGF-111In) and EGFR monoclonal antibody (Mr, 150 
kDa) labeled with 111In (MAb-111In), were compared for their biodistribution after 
being systemically injected into EGFR-expressing tumor-bearing mice.34 EGF-111In 
was rapidly cleared from the blood in the mice and achieved < 0.2% of the injected 
dose (% ID/g) in the blood at 72 h after injection. On the other hand, MAb-111In was 
eliminated more slowly with 3% at 72 h post-injection. Slow blood clearance of 
MAb-111In was attributed to its large molecular weight, which hampers its filtration 
at the kidney glomerulus. Proteins larger than 60 kDa are known to be non-filtered 
through the kidney.35 Despite rapid blood clearance of EGF-NP, the imaging agent 
enables clear visualization of the tumor 12 h post-injection. A short lag time 
between injection and imaging combined with a sufficient imaging contrast is 
advantageous, especially for monitoring applications such as monitoring of EGFR 
expression during a course of treatment. This short lag time facilitates repeated 
imaging acquisition within a short time frame. In addition, rapid clearance of the 




Development and characterization of an EGFR-targeted, fluorescently labeled and 
internally quenched probe (EGF-NP) were presented in this study. This probe is 
based on a natural ligand of EGFR, EGF (~6 kDa). EGF-NP was easily modified 
with fluorophores for labeling purposes and displayed high binding affinity for 
EGFR in vitro and in vivo. Also, EGF-NP takes the advantage of its small molecular 
weight compared to an antibody-fluorophore conjugate by having both rapid tumor 
localization and clearance from body. EGF-NP, as a protein-based imaging probe 
monitoring its target receptor, mechanistically met the chief requirements, such as 
specific binding affinity to the target receptor, a fast clearance from the body and 
tissue permeability. Therefore, this diagnostic in vivo imaging probe can be applied 
to choose patients for EGFR-targeted therapy and to monitor the therapeutic 
efficacy of EGFR-targeted drugs. 
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Detection of lysyl oxidase activity in 






The tumor stroma is characterized by remodeling and stiffening of the 
extracellular matrix (ECM).1-3 ECM comprises a heterogenous group of 
macromolecules, such as collagen, elastin, proteoglycans, noncollagenous 
glycoproteins, and elastic fibers.4 ECM is constantly remodeling by the 
simultaneous synthesis and degradation of ECM components with different turnover 
rates. ECM stiffening depends on the collagen cross-linking. During the formation 
of intramolecular or intermolecular cross-linking of collagen, collagen fibers change 
into increasingly insoluble and show progressively incremental stiffening.5,6 
Lysyl oxidase (LOX) is an ECM-remodeling enzyme that is frequently elevated in 
the tumor microenvironment.7, 8 Specifically, LOX oxidatively deaminates 
(hydroxyl)lysine residues, which form the aldehyde groups, yielding allysine 
(Figure 4.1). By enzymatic oxidation in the telopeptides of collagen by LOX, highly 
reactive aldehyde groups can react with adjacent aldehyde groups, rendering 
intramolecular cross-linking of collagen, or can react with other ε-amino groups of 
(hydroxyl)lysine residues of an adjacent helix, rendering the intermolecular cross-
linking of collagen. In this oxidative reaction process, hydrogen peroxide is released. 
Active LOX increases ECM stiffness, regulates cell migration, and promotes cancer 
malignancy.9 Indeed, excessive LOX has been correlated with poor prognosis and 
ECM stiffness in breast, colorectal, head and neck, and prostate cancer.10-12 
Therefore, sensitive detection of LOX activity is needed. 
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Recently, gold nanoparticle (AuNP)-based colorimetric sensors have attracted 
interest as a rapid and simple detection method.13 Stabilized AuNPs in solution 
present a characteristic absorption band at a specific wavelength due to plasmon 
resonance. This absorption band is red-shifted toward longer wavelengths by the 
aggregation of AuNPs, which causes that color of AuNP solution to turn from 
original pinkish red to blue/purple.14 This color change can be used to detect the 
presence or amount of analytes that cause the selective aggregation of AuNPs.15, 16 
In this study, the AuNPs were functionalized with the LOX-sensitive hexapeptides 
(LOX-AuNPs), which were applied to detect LOX as a colorimetric sensor in in 
vitro, cancer cell, and tumor tissue levels (Figure 4.2). The color and absorption 
spectra of AuNPs in solution was monitored before and after the addition of LOX in 
vitro. The potential use of LOX-AuNPs for detecting the amount of LOX in cancer 
cells was investigated, which was compared with the results of Western blot 
analysis and a commercially available LOX assay. Finally, the potential use of 
LOX-AuNPs in tumor tissues was examined, and tumor tissues were further 
analyzed for their collagen content and their ECM stiffness. 
 
4.2. Experimental section 




















 in the te
 react with 
residues of
104



















































































LOX enzyme was purchased from OriGene (Rockville, MD). MMP-2 and cathepsin 
B enzymes were purchased from R&D Systems, Inc. (Minneapolis, MN). LOX 
inhibitor, β-aminopropionitrile, was purchased from Sigma-Aldrich (St. Louis, MO). 
Fetal bovine serum (FBS) was purchased from Invitrogen Canada (Burlington, ON, 
Canada), and RPMI 1640 medium was obtained from Gibco (Grand Island, NY). 
For Western blot analysis, anti-LOX and a horseradish peroxidase-conjugated anti-
mouse antibody were purchased from Aviva Systems Biology (San Diego, CA) and 
Santa Cruz Biotechnology (Santa Cruz, CA), respectively. A commercially available 
LOX assay kit, AmpliteTM Fluorimetric Lysyl Oxidase Assay kit, was purchased 
from AAT Bioquest (Sunnyvale, CA).  
 
4.2.2. Synthesis of gold nanoparticles 
AuNPs were prepared according to the citrate reduction procedure.17 A solution of 
HAuCl4 (95 ml, 0.26 mM) was heated and equilibrated at 100 
oC in a reactor. Then, 
sodium citrate (0.5% [w/v]) dissolved in distilled water (DW, 5 ml) was injected, 
and the mixture was reacted at the boiling temperature for 30 min before letting it 
cool to room temperature. 
 
4.2.3. Preparation of peptide-functionalized gold nanoparticles 
LOX-sensitive peptide (LOX-peptide, Ala-Ala-Lys-Ala-Ala-Cys), LOX-
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insensitive peptide (Control-peptide, Ala-Ala-Ala-Ala-Ala-Cys), and LOX-
insensitive peptide 2 (Control-2-peptide, Ala-Ala-Gly-Ala-Ala-Cys) were 
synthesized using a standard solid-phase peptide synthesis method (Peptron, 
Daejeon, Korea).18 Peptide-functionalized AuNPs (1.3 nM) were prepared by 
mixing the freshly prepared AuNPs in DW (1 ml) with an aqueous solution of LOX-
peptide or Control-peptide (5 mg/ml, 0.1 ml), yielding LOX-AuNPs or Control-
AuNPs, respectively. After reacting at room temperature for 1 h, peptide-
functionalized AuNPs were purified by centrifugation and washing with DW twice, 
and were re-dispersed in DW (1.3 nM). The dispersed AuNPs were stored at 4C for 
further use. 
 
4.2.4. Characterization of peptide-functionalized gold nanoparticles 
The peptides treated with LOX enzyme were characterized by analytical reverse 
phase-high performance liquid chromatography (RP-HPLC); 20% to 80% 
acetonitrile containing 0.1% trifluoroacetic acid (TFA) versus DW containing 0.1% 
TFA over 30 min at a flow rate of 1.0 ml/min. Mass spectrometry was used to 
measure the molecular weight of the peptides treated with LOX enzyme using 
Varian 500-MS (Varian Inc., Palo Alto, CA). The mean diameter and size 
distribution of the AuNPs and LOX-AuNPs were observed with dynamic light 
scattering (DLS) at 25C. UV/Vis absorbance of AuNPs or peptide-labeled AuNPs 
with or without various enzymes was recorded from 400 to 700 nm using UV/Vis 
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spectrophotometer (Optizen 2120, Mecasys, Daejeon, Korea). AuNP aggregates 
were observed using transmission electron microscopy (TEM, CM30 
electronmicroscope, Philips, CA) operating at 80 kV. The sample solution was 
placed on the grid for 2 min and excess solution was blotted with filter paper. For 
staining, the grid was placed on a drop of 2% (w/v) uranyl acetate. 
 
4.2.5. Sensitivity and specificity of peptide-functionalized gold 
nanoparticles for lysyl oxidase 
The sensitivity of the LOX-AuNPs or Control-AuNPs was examined by 
incubating LOX-AuNPs (1.3 nM) in DW containing various concentrations (6.0, 
12.0, 24.0, 48.0, and 96.0 nM) of LOX enzymes. Color change was observed, and 
the UV/Vis absorbance of LOX-AuNPs or Control-AuNPs was monitored. The 
specificity of the LOX-AuNPs was examined by incubating LOX-AuNPs (1.3 nM) 
in DW containing 15 nM of activated MMP, cathepsin and LOX plus LOX inhibitor. 
Color change and the UV/Vis absorbance of LOX-AuNPs were monitored. 
 
4.2.6. Cell culture  
Human breast cancer cell lines, MCF-7 and MDA-MB-231 were maintained in an 
RPMI 1640 medium containing 10% (v/v) FBS and penicillin G (100 
U/ml)/streptomycin (100 μg/ml) at 37C, 5% CO2. MCF-7 (1×106 cells/dish) and 
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MDA-MB-231 (1×106 cells/dish) were plated on a 100-mm tissue culture dish. 
MCF-7 and MDA-MB-231 were cultured for 24, 48, or 72 h, respectively. LOX-
containing conditioned media were collected from MCF-7 or MDA-MB-231. 
 
4.2.7. Commercially available lysyl oxidase assay 
A commercially available LOX activity assay kit, the AmpliteTM Fluorimetric 
Lysyl Oxidase Assay Kit was utilized to validate the LOX-AuNPs-based results. 
The AmpliteTM Fluorimetric Lysyl Oxidase Assay is a fluorescence signal-based 
method for detecting LOX. This assay utilizes a proprietary LOX substrate that can 
release hydrogen peroxide when reacted with LOX. In this assay, LOX activity was 
indirectly detected by measuring the production of hydrogen peroxide. In practice, 
conditioned media (50 µl) was added to the assay reaction mixture (50 µl) in 96-
well plate. After incubating 30 min at 37C, the signal was read at 576 nm by an 
absorbance plate reader. 
 
4.2.8. Tumor models 
All animal experimental procedures were in compliance with the institutional 
guidelines of Korea Institute of Science and Technology and the relevant laws. 
MCF-7 (1  106 cells/mouse) and MDA-MB-231 cells (1  107 cells/mouse) 
suspended in phosphate-buffered saline (PBS, 100 l) were subcutaneously injected 
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into the left flank of athymic nude mice (20 g, Orient, Seoul, Korea), respectively. 
The LOX inhibitor (3 mg/kg body weight) was intraperitoneally injected every day 
from 14 days after the injection of tumor cells. When tumors reached 5.0 ± 0.5 mm 
in diameter, the tumors were excised for further analysis. For protein extraction, 
excised tumor tissues were grounded by liquid nitrogen, rinsed with PBS, and 
sonicated in lysis buffer (7 M urea, 2 M thiourea, 4% [v/v] CHAPS, 130 mM 
dithiothreitol, 1 mM NaF, Na2VO3, and a complete protein inhibitor mixture) for 20 
min. The samples were then centrifuged at 9700 g for 15 min. The protein 
concentration in the supernatant was measured based on a Bradford assay (Bio-Rad 
protein assay kit; Bio-Rad, Hercules, CA). 
 
4.2.9. Histological and Western blot analyses 
Excised tumor tissues were fixed in 4% (v/v) buffered formalin, dehydrated with a 
graded ethanol series, and embedded in paraffin. The specimens were cut into 5 m-
thick sections and stained using the Masson’s Trichrome method to detect collagen. 
For immunohistochemistry (IHC) analysis, sections were stained with primary 
antibodies against LOX. The staining signals were developed with a Histostain®-
Plus Kit (Invitrogen). The nucleus was stained with 4',6-diamidino-2-phenylindole 
(DAPI).  
For Western blot analysis, each aliquot of the cell supernatant or extracted proteins 
mixed with a sample buffer (0.25 M of Tris, 0.8% [w/v] sodium dodecyl sulfate, 10% 
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[v/v] glycerol, 0.05% [w/v] bromophenol blue, pH 6.8) was run on 10% 
polyacrylamide gel after boiling (10 min). Gels were transferred to a blot membrane 
using iBLOT (Invitrogen). Membranes were blocked with milk in Tris-buffered 
saline-Tween20 (TBST) at room temperature for 1 h and then incubated with anti-
LOX at 4C overnight. Three washes (15 min each) with TBST were performed, 
and the membranes were incubated with a horseradish peroxidase-conjugated anti-
mouse antibody for 1 h in TBST and then washed (three washes, 15 min each) with 
TBST. β-actin was used as internal control. Immunoreactive proteins were 
visualized with enhanced chemiluminescence.  
 
4.2.10. Compressive modulus measurements 
Compression testing was performed on cylinidrical shape-cutting tumor tissues 
using an electro-metchanical driven indenter (Instron 5966) including a force 
transducer (a load cell of 10 N), a stepper motor, and a linear displacement 
transducer.1, 19 The tangent elastic moduli of the tumor tissues were calculated from 
the initial linear slope in the resulting stress-strain curves. 
 
4.2.11. Statistical analysis 
Data represents the means  standard deviation. A one-way analysis of variance 
was used for the comparison of variables between groups. A value of p < 0.05 was 
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considered statistically significant. 
 
4.3. Results 
4.3.1. Reactivity of lysyl oxidase-peptide for lysyl oxidase 
Hexapeptide containing lysine (LOX-peptide) showed a distinct response to LOX, 
while hexapeptides without lysine (Control-peptide, Control-2-peptide) did not 
respond to LOX. LOX is known to deaminate lysine to allysine which is highly 
reactive. Aldehyde groups in allysine can react with adjacent aldehyde groups or 
with ε-amino group of a lysine residue.20 The products before and after addition of 
LOX were evaluated by analytical RP-HPLC and mass spectroscopy (Figure 4.3). 
The HPLC profiles of the LOX-peptide after the addition of LOX showed one main 
peak, which is different from that before the addition of LOX. Mass spectrometry 
showed a peak at 575.8 Da in the product before the addition of LOX. After the 
addition of LOX, it showed an additional peak at 1151.3 Da, indicating the 
conjugation between two LOX-peptides. However, Control-peptide did not show 
any change in the results of HPLC and mass spectroscopy after the addition of LOX.  
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The peptide-functionalized AuNPs were prepared in DW using LOX-peptide and 
Control-peptide. Because thiol groups interact strongly with AuNPs, hexapeptides 
used in this study were designed to contain cysteine in one side of peptide. The 
hydrodynamic diameter of AuNPs grew from 14.76 ± 0.38 nm in diameter to 24.76 
± 0.29 nm in diameter in DLS analysis, confirming the presence of peptides on the 
surface of AuNPs (Figure 4.4 a). TEM measurements showed that both AuNPs and 
LOX-AuNPs are spherical shape with the similar size range of 13–20 nm. In 
addition, the surface plasmon resonance peak of AuNPs red-shifted from 518 nm to 
522 nm after being modified with LOX-peptide (Figure 4.4 b). The surface charge 
of AuNPs, zeta-potential was -30.0 ± 5.6 mV in AuNPs, and changed to 21.5± 0.6 
mV in LOX-AuNPs (Table 4.1). 
 
4.3.3. Detection of lysyl oxidase in vitro  
A series of concentrations of LOX were added to LOX-AuNPs in DW (1.3 nM, 1 
ml). By incubating these mixtures for 1 h, the solution color was observed and 
UV/Vis absorbance was monitored. The solution turned from the original pinkish 
red to purple (Figure 4.5 a) and the absorption spectra of the LOX-AuNPs red-
shifted and broadened with increasing LOX concentrations (Figure 4.5 d). The 
plasmon band shifted from 522 nm at 0 nM LOX and to 592 nm at 96 nM LOX. 
The spectral shifts appeared at concentrations as low as 12 nM. LOX-AuNPs was 
























































whereas it was found to form aggregates in the presence of LOX (Figure 4.5). 
Quantitative analysis was performed by measuring the absorbance values of 
A650/A520. The calibration curve for LOX quantification showed the linear range 
(r2 = 0.999) from 12 nM to 96 nM (Figure 4.5 e). Meanwhile, any noticeable 
changes in the UV/Vis spectra or color of the resulting AuNPs were not shown 
when other enzymes including MMP or cathepsin were added to LOX-AuNPs 
(Figure 4.6). In addition, pretreatment of LOX inhibitor prevented changes in the 
UV/Vis spectra or color of the resulting AuNPs. No change in the UV/Vis spectra or 
color of the resulting AuNPs was observed when a series of concentrations of LOX 
was added to Control-AuNPs. 
 
4.3.4. Detection of lysyl oxidase in cancer cells 
To investigate the potential use of LOX-AuNPs, they were applied to determine 
LOX in cancer cells with different LOX contents. MDA-MB-231 and MCF-7 cells 
were selected as high LOX-secreting and low LOX-secreting cells, respectively.21 
LOX is a secreted enzyme, hence, LOX detection was performed in the conditioned 
media using LOX-AuNPs, Western blot analysis, and a commercially available 
LOX assay kit. When the conditioned media after a 3-day culture of MDA-MB-231 
cells were added to LOX-AuNP solution, color change and spectral shifts were 
more dramatic compared to that after a 3-day culture of MCF-7 cells (Figure 4.7). 
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to 3 days, color change and spectral shifts increased as well. LOX expression in the 
conditioned media after a 3-day culture of MDA-MB-231 cells was barely 
detectable in Western blot analysis (Figure 4.7 d). LOX expression in the other 
conditioned media was not detected in Western blot analysis. A commercially 
available LOX assay, the AmpliteTM Fluorimetric Lysyl Oxidase Assay is a 
fluorescence signal-based method for detecting hydrogen peroxide released in the 
reaction between a LOX substrate and LOX.22 Importantly, LOX activity from the 
commercial assay revealed a very similar tendency but lowered sensitivity as 
measured in the LOX-AuNP assay results (Figure 4.7 e). 
 
4.3.5. Detection of lysyl oxidase in tumor tissues 
To investigate potential for the use of LOX-AuNPs, they were applied to 
determine LOX in tumor tissues with different LOX contents. When tumors reached 
7.0 ± 0.5 mm in diameter, MDA-MB-231 tumors, MDA-MB-231 tumors treated 
with LOX inhibitor, and MCF-7 tumors were excised, and proteins were extracted. 
Western blot analysis indicated higher levels of LOX expression in MDA-MB-231 
tumors, compared to those of MDA-MB-231 tumors treated with LOX inhibitor and 
MCF-7 tumors (Figure 4.8 a). Proteins extracted from respective tumor tissues were 
added to LOX-AuNP solution. Distinct color changes and spectral shifts in the 
plasmon band were correlated with the LOX contents analyzed by Western blot 
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4.3.6. Analysis of extracellular matrix remodeling in tumors 
IHC against LOX antibody showed strong LOX expression in MDA-MB-231 
tumors and limited LOX expression in MCF-7 tumors. In addition, reduced LOX 
expression was present in MDA-MB-231 tumors treated with LOX inhibitor. Next, 
the amount of collagen tumor tissue was evaluated using Masson’s Trichrome 
staining. Collagen in fibrils was stained to be blue with Masson’s Trichrome. 
Phosphomolybdic acid, which is highly acid, binds to collagen in Masson’s 
Trichrome staining, which appears blue. Higher amounts of fibrillar collagens 
present within the MDA-MB-231 tumors appeared blue compared to MCF-7 tumors. 
In addition, MDA-MB-231 tumors treated with LOX inhibitor somewhat lost their 
collagen-containing fibrils. Compression testing revealed an incremental stiffening 
of the MBA-MB-231 tumors compared to MCF-7 tumors (Figure 4.8 d). The elastic 
modulus of MCF-7 tumors (52 ± 12 kPa) was found to decrease by 89% compared 
with MBA-MB-231 tumors (457 ± 171 kPa). LOX-inhibitor-treated MBA-MB-231 
tumors (402 ± 121 kPa) have a slightly lower value than MBA-MB-231 tumors 
without LOX-inhibitor treatment. 
 
4.4. Discussion 
A significant amount of experimental evidence provides support for the notion that 




























































































progression: a number of studies have demonstrated that LOX activity is closely 
correlated with tumors’ stiffness and invasiveness of cancer.1, 11, 23 In this study, 
AuNPs functionalized with LOX-sensitive peptides were applied to detect presence 
or amount of LOX in in vitro, cancer cell, and tumor tissue levels.  
It was assumed that the peptides that have been reactive by LOX on AuNPs can 
bind to adjacent molecules, which can result in the aggregation of AuNPs via 
bridging of neighboring AuNPs. The spectral shift and color change of AuNPs is 
well known to occur due to the change of the aggregate size and interparticle 
spacing.24, 25 In this study, the absorption spectra red-shifted and broadened with 
increasing LOX. Also, an obvious color change was observed from red to purple. 
Further supporting evidence of the aggregation of LOX-AuNPs was gathered by 
TEM imaging. TEM images displayed that the well-dispersed LOX-AuNPs before 
addition of LOX, assembled into AuNP aggregates after addition of LOX. These 
results in the LOX-AuNP solution together indicate that LOX induces the 
aggregation and following spectral shift and color change of AuNP. 
The presence or amount of LOX can be directly observed by the color variation of 
the AuNP solution with the “naked eye” or quantified with absorption spectral 
measurements in the LOX-AuNP assay. Analyzing method using LOX-AuNPs in 
this study showed detection limit in the nanomolar range of LOX concentration. A 
commercially available LOX assay indirectly detects the production of hydrogen 
peroxide released from reaction between LOX substrate and LOX. However, 
hydrogen peroxide can be generated by multiple enzymes and in multiple cellular 
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compartments besides LOX reactions in cancer tissue.26, 27 Indeed, aberrant 
generation of hydrogen peroxide is known to be correlated with the development 
and progression of cancer.26, 28 Based on these results, the LOX-AuNP method is 
sensitive, rapid, simple, and has potential for use in colorimetric sensors.29  
Active LOX has been known to increase collagen cross-linking and subsequent 
ECM stiffness. Indeed, the levels of LOX measured using LOX-AuNPs in various 
tumor tissues correlated directly with their collagen contents measured with 
Masson’s Trichrome staining and ECM stiffness measured with tensile loading 
assay. The elastic modulus of MDA-MB-231 tumors was significantly higher than 
that of MCF-7 tumors and was slightly higher than that of MDA-MB-231 tumors 
treated with LOX inhibitor. This is consistent with the previous findings.1, 22 LOX 
inhibitor β-aminopropionitrile hinders collagen cross-linking and lowers ECM 
stiffness in vivo. In addition, ECM stiffness is known to be closely related with 
cancer progression and metastasis. Measured stiffness in this study is correlated 
with previously reported invasive properties of cancer; MDA-MB-231 cells are 
known as a highly invasive/metastatic breast cancer cell line, while MCF-7 cells are 
part of a poorly invasive/nonmetastatic breast cancer cell line.30, 31  
 
4.5. Conclusions 
LOX, an ECM-remodeling enzyme, is known to strongly affect ECM stiffness via 
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the cross-linking of collagen. AuNPs functionalized with LOX-sensitive 
hexapeptides were applied to detect LOX as a colorimetric sensor in in vitro, cancer 
cell, and tumor tissue levels. Importantly, when LOX-AuNP was applied to various 
tumor tissues, the levels of LOX measured using LOX-AuNPs in various tumor 
tissues correlated directly with their collagen content measured with Masson’s 
Trichrome staining and ECM stiffness measured with tensile loading assay. LOX-
AuNPs may be useful for detecting LOX activity and further ECM stiffness of 
tumor tissues.  
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Successful surgical procedures for cancer treatment depend on the accurate and 
rapid localization of tumor tissues, following their correct resection.1 If the 
localization of tumors can be displayed in a simple and rapid fashion due to 
differentiation between tumor and normal tissues, it allows complete tumor 
resection while preserving important structures like nerves, ureters, and blood 
vessels.2 Optical fluorescence imaging is an ideal technology for intra-operative 
procedures because it offers highly attractive properties, including high sensitivity, 
real-time image acquisition, portability, low cost, and the absence of ionizing 
radiation.3 Fluorescently labeled probes that can expose the difference between 
tumor and normal tissues can be a favorable approach for the intra-operative 
detection of cancer.  
There are several structural differences between tumor and normal tissues (Figure 
5.1).4 A prominent characteristic of tumor tissues is increased microvessel density, 
especially in peripheral tumor regions and deficiencies in blood and lymphatic 
vessel function. Dense vascularization is known to be present in a tumor’s periphery. 
Blood vessels in tumor tissues are known to be leaky and irregularly dilated, unlike 
normal blood vessels. Moreover, lymphatic vessels in tumors are lacking, which 
results in the inefficient drainage of interstitial fluid and proteins from the tumor 
tissue. Another characteristic of tumor tissue is the modified composition and 
density of the extracellular matrix (ECM). The ECM is composed of a loose 
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connective network of collagen, elastin, laminin, and fibronectin in normal tissues. 
Meanwhile, the ECM in tumor tissues include a much denser and thicker network 
consisting of different compositions compared to normal tissues. These differences 
between tumor and normal tissues can contribute to the selective detection of 
tumors. 
The extent of drug distribution throughout the body may be represented by the 
volume of distribution (Vd), the proportionality factor that relates the total amount 
of a drug in the body to its concentration in the blood at a steady state.5 A higher Vd 
indicates that a larger amount of the drug has been distributed in the tissue, 
suggesting it could be highly permeable to the tissue.6 In the present study, it was 
hypothesized that 1) drugs with high Vd can penetrate more deeply into the tissue 
compared to drugs with a low Vd, and 2) they can differently accumulated in tumor 
or normal tissues due to the structural differences between them. To verify this 
hypothesis, four drugs with different Vd values were selected: raloxifene, 
scopolamine, ampicillin, and ibuprofen (Table 5.1).7-9 The near-infrared dye, 
FCR675 was conjugated to the drugs to visualize localization of the drugs in vivo 
and ex vivo in this study. Four drug-dye conjugates were synthesized, topically 
applied via spraying onto an HCT116-luc tumor, and transanally applied via the 
anus into descending colon of colon tumor-bearing mice (Figure 5.2). The topical 
application via spraying of the probe can be achieved with reduced doses in a 
simple and rapid fashion compared to systemic application.1 The localization of the 
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2348 L/kg 3.1 L/kg 0.38 L/kg 0.1 L/kg
LogP 5.4 0.89 0.46 3.8



























5.2. Experimental section 
5.2.1. Materials 
FCR675 (excitation/emission; 674/699 nm) was purchased from Bioacts (Incheon, 
Korea). Raloxifene hydrochloride, scopolamine hydrochloride, ampicillin sodium, 
and ibuprofen were purchased from Sigma-Aldrich (St. Louis, MO). CD31 and von 
Willebrand Factor (vWF) antibodies were purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA), and horseradish peroxidase-conjugated anti-
mouse antibody was purchased from Waters (Milford, MA). DMEM and RPMI 
1640 were purchased from Gibco (Grand Island, NY).  
 
5.2.2. Synthesis of drug-dye conjugates  
To develop the Ralo-FCR675 and Sco-FCR675 conjugates, raloxifene 
hydrochloride (1.0 mmol), and scopolamine hydrochloride (1.0 mmol) were 
incubated in a 1:9 (v/v; 0.5 ml) triethylamine (TEA)/dimethylformamide (DMF) for 
20 min for desalting, respectively. The FCR675 carboxylic acid (2.0 mmol) was 
mixed with diisopropylcarbodiimide (DIC; 1.0 mmol) and N,N’-
dimethylaminopyridine (DIPEA; 4.0 mmol) in DMF (0.5 ml), and the reaction 
mixture was then stirred at room temperature (RT) for at least 10 min. Desalted 
raloxifene and scopolamine in TEA/DMF were added to the FCR675 mixture, and 
stirred at RT for 6 h. To develop the Ampi-FCR675 conjugate, ampicillin sodium 
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(1.2 mmol) was mixed with FCR675 N-hydroxysuccinamide (NHS) ester (1.0 
mmol) in DMF (0.5 ml). To synthesize the Ibu-FCR675 conjugate, ibuprofen (1.0 
mmol) was mixed with DIPEA (2.0 mmol) and 1-[bis(dimethylamino)methylene]-
1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU; 1.2 mmol) 
that had been dissolving in DMF for 15 min. Then, the activated ibuprofen was 
mixed with the FCR675 amine that had been dissolved in DMF in the dark and 
shaken overnight. The product was purified by semi-preparative reverse phase-high 
performance liquid chromatography (RP-HPLC) using 5% to 95% acetonitrile 
containing 0.1% trifluoroacetic acid (TFA) versus distilled water (DW) containing 
TFA over 25 min at a flow rate of 5 ml/min. The appropriate fractions were 
collected and lyophilized.  
 
5.2.3. Characterization of drug-dye conjugates 
Four drug-dye conjugates were characterized by analytical RP-HPLC using 30% 
to 90% acetonitrile containing 0.1% TFA versus DW containing TFA over 20 min at 
a flow rate of 1 ml/min. Matrix-assisted laser desorption/ionization-time of flight 
(MALDI-TOF) mass spectrometry was utilized to quantify the molecular weight of 
four drug-dye conjugates using a MALDI-TOF system (Microflex LRF20, Bruker 
Daltonics, Bremen, Germany). The partition coefficients (logP) of drug-dye 
conjugates were determined using the RP-HPLC method.10 The calibration curve 
was drawn using the retention time and logP of the standard substances, including 
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ethyl acetate, nitrobenzene, toluene, 1,2-dichlorobenzene, and phenanthrene (Figure 
5.2). In this calibration curve, logk’ means log[(TR-T0)/T0], and TR and T0 indicate 
retention time of sample and non-retained substance, respectively. The retention 
time of the drug-dye conjugates was converted to a logP scale through a calibration 
curve. 
 
5.2.4. Cytotoxicity and cellular uptake 
The cytotoxicity of drug-dye conjugates was evaluated with a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Fire fly 
luciferase (luc) gene-transfected human colorectal carcinoma cells (HCT116-luc) 
were maintained in an RPMI 1640 medium containing 10% (v/v) fetal bovine serum 
and penicillin G (100 U/ml)/streptomycin (100 μg/ml) at 37C, 5% CO2. HCT116-
luc cells (1  104 cells/well) were seeded in a 96-well plate and maintained for 12 h. 
The various concentrations of the four drug-dye conjugates and the free dye (0.1, 
1.0, 5.0, 10, 25, 50 μM) were added to each well of the cell and then incubated for 
24 h. The MTT solution was added and incubated for 2 h, and absorbance was 
observed at 570 nm with a plate reader. Cell viability was calculated as the 
percentage of viable cells relative to untreated cells. The experiment was performed 
in triplicate. 
To investigate the cellular uptake of Ralo-FCR675, HCT116-luc cells were plated 
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in 35-mm covered glass-bottomed dishes and incubated for 48 h. Various 
concentrations of Ralo-FCR675 (0, 1.25, 2.5, 5.0 M) were treated in each cell 
culture and incubated for 2 h. The cells were stained with 4',6-diamidino-2-
phenylindole (DAPI). The samples were observed using a confocal laser scanning 
microscope (Leica SP5, Leica Microsystems, Buffalo, Grove, IL). 
 
5.2.5. Liver tumor model 
All animal experimental procedures were in compliance with the institutional 
guidelines of Korea Institute of Science and Technology and the relevant laws. A 
tumor was induced in male athymic BAL/c nude mice (20 g, Orient, Korea), and the 
mice were anesthetized with an intraperitoneal injection of xylazine (10 mg/kg body 
weight) and ketamine (80 mg/kg body weight). A paramidline abdominal incision 
was made to expose the liver. Then, HCT116-luc cells (3  105 cells/mouse) 
suspended in 20 l of sterile saline were injected into the left lobe of each mouse’s 
liver under the capsule. After the injection of tumor cells, the paramidline incision 
was sutured with 4-0 black silk. 
 
5.2.6. Topical application via spraying of drug-dye conjugates  
Fourteen days after the injection of the HCT116-luc cells into the liver, the liver 
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was once again exposed via a paramidline abdominal incision. Four drug-dye 
conjugates and the free dye (FCR675) were topically applied by spraying the 
surface of the HCT116-luc tumor in the liver. Before application, the fluorescence 
intensities of the four drug-dye conjugates and the free dye were adjusted using a 
Kodak image station (4000MM; Kodak, New Haven, CT) equipped with a cooled 
charged-coupled device video camera (CCD camera; Kodak, Japan), a special C-
mount lens, and a Cy5.5 bandpass emission filter (680-720 nm). After incubating 
for 3 min, the tissue was washed three times with phosphate-buffered saline (PBS).  
 
5.2.7. In vivo and ex vivo fluorescence imaging  
To quantify the drugs’ circulation time in the blood, Ralo-FCR675, Sco-FCR675, 
Ampi-FCR675, and Ibu-FCR675 were intravenously injected into the tail vein. One 
milliliter of blood samples (n=3) were drawn from the mice at pre-determined time 
points and were centrifuged at 4000 rpm for 10 min at 4C. A Kodak image station 
captured NIR fluorescence images of the supernatant fractions.  
After topical application via spraying for 3 min and subsequent washing, an IVIS 
Spectrum imaging system (Caliper Life Sciences, Hopkinton, MA) captured NIR 
fluorescence and bioluminescence images in vivo. For bioluminescence imaging, a 
D-luciferin solution (150 mg/kg body weight) was intraperitoneally injected 10 min 
prior to imaging. The total photon counts from pre-defined regions of interest (ROI) 
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in each animal were calculated using Living Image software (Caliper Life Sciences). 
After the in vivo NIR fluorescence imaging, the mouse was sacrificed, and the liver 
was excised and imaged using the IVIS Spectrum imaging system.  
Ex vivo NIR fluorescence of excised liver tumor was captured with a small animal 
imaging system (OV100, Olympus, Japan). Ralo-FCR675 and FCR675 were 
topically applied via spraying on the exposed liver through a paramidline abdominal 
incision in live mice. After 3 min of incubation and washing, the liver was excised 
and sliced at 400 µm thickness to observe the penetration of the Ralo-FCR675 and 
FCR675 along the depth of the tumor. Fluorescence images of the liver tumor were 
taken using OV-100 with 620-650 nm/680-710 nm (Ex/Em) channel. 
 
5.2.8. Azoxymethane-induced colon cancer model 
Male A/J mice (6 weeks old, Orient, Korea) were injected intraperitoneally with 
10 mg/kg of azoxymethane (AOM) dissolved in PBS once a week for 8 weeks.11, 12 
The mice were anesthetized by inhalation of isoflurane. A midline abdominal 
incision was made to expose the colon. Ralo-FCR675 (5 μM, 500 μl) was 
administered via the anus into descending colon with a plastic needle. The anus and 
transverse colon were immediately clamped with blunt forceps for 3 min. The colon 
was washed three times by PBS and carefully excised. Excised colons were imaged 
by an IVIS Spectrum imaging system. The colon lesions exhibited high 
fluorescence signals were analyzed with hematoxylin and eosin (H&E) staining. 
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5.2.9. Histological analysis  
Each excised liver was divided into two pieces. One piece was embedded into an 
optimal cutting-temperature (OCT) compound for cryosection preparation and 
further fluorescence microscopy analysis. The other piece was fixed in a 4% (v/v) 
buffered formalin and then embedded in paraffin. 8 m-thick frozen sections cut 
from the OCT-embedded specimens were stained with DAPI and observed for 
microscopic imaging of Cy5.5 and DAPI fluorescence. Meanwhile, 4 m-thick 
sections cut from the paraffin-embedded tissues were stained with H&E or 
Masson’s trichrome. In addition, the paraffin sections were stained with the primary 
antibodies against endothelial cell markers, von Willebrand Factor (vWF) and CD31. 
The staining signal was developed with a Histostain®-Plus Kit. Sections were 
counterstained with Harris’s hematoxylin. 
 
5.3. Results 
5.3.1. Characterization of drug-dye conjugates  
Four drug-dye conjugates were synthesized by directly coupling FCR675 with 
raloxifene, scopolamine, ampicillin, and ibuprofen (Figure 5.2 b). FCR675 acid in 
the presence of DIC and DIPEA was coupled with a hydroxyl group of raloxifene 
and scopolamine, respectively, to afford Ralo-FCR675 and Sco-FCR675. FCR675 
NHS ester was conjugated to an amine group of ampicillin sodium in DMF to 
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synthesize Ampi-FCR675. Ibuprofen was reacted with the FCR675 amine using 
HATU and DIPEA as coupling reagents to produce the Ibu-FCR675 conjugate. All 
drug-dye conjugates were purified using RP-HPLC, rendering > 95% purity of all 
conjugates (data not shown).  
Formation of the drug-dye conjugates was confirmed with mass spectrometry 
analysis. Each conjugate analyzed by MALDI-TOF displayed a mass in agreement 
with the calculated values (calculated for Ralo-FCR675: 1370, found: 1371; 
calculated for Sco-FCR675: 1201, found: 1202; calculated for Ampi-FCR675: 1268, 
found: 1267; calculated for Ibu-FCR675: 1147, found: 1147) (Figure 5.4, Table 5.2). 
The partition coefficient (logP) of the drugs used in this study ranges between 0.46 
and 5.4. However, the logP of the drug-dye conjugates drawn from the standard 
curve narrowly ranges between 0.87 and 1.3 after conjugating with FCR675 (Figure 
5.3, Table 5.2). 
To evaluate the cytotoxicity of the drug-dye conjugates, the viability of HCT116-
luc cells was measured using a MTT (Figure 5.5 a). The HCT116-luc cells were 
treated with various concentrations of the drug-dye conjugates (0.1, 1.0, 5.0, 10, 25, 
and 50 μM). All drug-dye conjugates and the free dye exhibited cell viability > 95% 
at all concentrations up to 50 M. Cellular uptake of Ralo-FCR675 was evaluated in 
HCT116-luc cells. Increasing fluorescence intensity was observed in the cells with 
higher concentrations of treated Ralo-FCR657 (Figure 5.5 b). Ralo-FCR675 
displayed fluorescence signals in both the cytoplasm and the nuclei. 
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Figure 5.3. Calibration curve drawn using retention time and partition coefficient 
(logP) of the standard substance including ethyl acetate, nitrobenzene, toluene, 1,2-





























Ralo-FCR675 Sco-FCR675 Ampi-FCR675 Ibu-FCR675
Molecular
Weight
1371 1202 1267 1147
LogP 1.3 1.0 0.87 1.2
Table 5.2. Molecular weight and logP of drug-dye conjugates
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Figure 5.4. Mass spectrometry of (a) Ralo-FCR675, (b) Sco-FCR675, (c) Ampi-









































































To measure how fast the drug-dye conjugates extravasate from blood vessels, the 
blood samples obtained from mice after intravenous administration of the drug-dye 
conjugates were analyzed. Ralo-FCR675 demonstrated weak fluorescence intensity 
(fluorescence intensity: 676 ± 44) in the blood even at 15 min after intravenous 
injection. However, Ibu-FCR675 showed exceptionally strong fluorescence 
intensity (fluorescence intensity: 2632 ± 245) at 15 min after intravenous injection 
and considerable fluorescence intensity (fluorescence intensity: 1141 ± 41) in the 
blood at 360 min after intravenous injection (Figure 5.6). The conjugates remained 
in the blood, in ascending order, is as follows: Ralo-FCR675, Sco-FCR675, Ampi-
FCR675, and Ibu-FCR675. The Vd value of the drug-dye conjugates was not 
directly measured; however, the circulating time of the drug-dye conjugates in 
blood can represent the property of Vd, in part. 
 
5.3.2. Preferential accumulation of drug-dye conjugates in tumors 
To evaluate the distribution of the drug-dye conjugates in the tumors, 100 μl of 25 
μM four drug-dye conjugates and the free dye (FCR675) in PBS were topically 
applied via spraying on the liver surface of the HCT116 liver tumor-bearing mice. 
The tumors were induced in the liver using luciferase-transfected HCT116 tumor 
cells. Drug-dye conjugates were simultaneously sprayed both on the surface of the 
tumors and in non-tumor regions. After spraying, the livers was preserved for 3 min 



























































































of this study. The presence and location of tumors in mice were measured with 
bioluminescence. Ralo-FCR675 exhibited the strongest fluorescence in the images 
from the IVIS Spectrum imaging system, and the location of this signal was 
significantly matched with the tumor region (Figure 5.7). Conversely, minimal NIR 
fluorescence remained on the liver tumor surface when Ibu-FCR675 and FCR675 
were applied. Importantly, cross-section images of the livers presented penetration 
depth of the drug-dye conjugates. Ralo-FCR675 penetrated the tumors to a 
maximum depth (up to 3 mm below the surface); Sco-FCR675 penetrated to half the 
tumors’ maximum depth (up to 1.5 mm below the surface); and Ampi-FCR675, Ibu-
FCR675, and FCR675 rarely penetrated into the tumors (< 0.5 mm below the 
surface) (Figure 5.7). In addition, selective accumulation and high permeability of 
Ralo-FCR675 in the tumor tissue was confirmed by the images from the OV100 
imaging system (Figure 5.7). On the other hand, FCR675 was rarely present in the 
tissues. 
  
5.3.3. Analysis of the distribution of drug-dye conjugates 
The rapid penetration of Ralo-FCR675 was displayed in tumor sections (Figure 
5.8 a). Twenty, 40, and 60 seconds after spraying, the livers were immediately 
excised and frozen. As the incubation time became longer, increasing penetration of 
Ralo-FCR675 was observed in the tumor tissue. Within 60 s, Ralo-FCR675 













 (NIR) FI an
e conjugates
or-bearing 
t along the g




d BLI of ex

























IR FI and B
























5.7. In vivo 
 fluorescenc
(e) Ex vivo 
ical applic
l NIR FI o
. The livers 
and ex vivo
e signal int
NIR FI of e
ation via sp


































conjugates was further confirmed by analyzing fluorescence in tumor and normal 
sections. Ralo-FCR675 was confirmed to penetrate most deeply into the tumor 
tissue among the drug-dye conjugates studied (Figure 5.8 b). When Sco-FCR675 
and Ampi-FCR675 were topically applied, their fluorescence intensity was strong 
near the tumor surface and then drastically diminished on the way to the tumor core. 
When Ibu-FCR675 and FCR675 were sprayed on the tumors, minimal fluorescence 
intensity was found throughout the tumor tissue. Unlike the preferential 
accumulation in tumor regions, minimal fluorescence intensity was found 
throughout the normal tissue when all drug-dye conjugates were topically applied. 
These data indicated that the drug-dye conjugate preferentially accumulated in 
tumor tissue. 
H&E analysis confirmed the presence of the HCT116 tumors in all excised livers 
(Figure 5.9 a). Substantially deposited collagens in the basement membrane 
appeared blue in the tumor tissue through Masson’s trichrome staining (Figure 5.9 
b). Fibrillar collagens present within the tumor mass appeared blue, whereas the 
sections from normal livers appeared red in the basement membrane without signs 
of collagen deposition (Figure 5.9 c). Anti-vWF and anti-CD31 immunostaining 
revealed that denser blood vessels existed in the tumor periphery compared to 
normal tissues (Figure 5.9).  
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Colon tumors developed in the descending colon of mice treated with AOM, as 
described previously.12 The Ralo-FCR675 (5 μM/500 μl PBS/mouse) was applied 
via the anus into the descending colon of colon tumor-bearing mice and maintained 
inside the descending colon for 3 min by clamping between the anus and transverse 
colon. Then, the colon tissue was washed three times with PBS, and the tumor-
bearing mice were sacrificed. The cancer lesions of the excised colon demonstrated 
high fluorescence intensity compared with adjacent mucosa in the NIR ex vivo 
image (Figure 5.10 b). Colon lesions demonstrating a high fluorescence signal 
revealed well-differentiated carcinomas in H&E stain (Figure 5.10 c).  
 
5.4. Discussion 
A number of studies have demonstrated various approaches to the intra-operative 
detection of tumors.1, 2, 13, 14 In this study, it was investigated whether fluorescently 
labeled drugs with high Vd selectively accumulated into tumor, not in normal tissue, 
which enabled visualization of the tumor. Drugs with different Vd values were 
selected: raloxifene (2348 l/kg), scopolamine (3.1 l/kg), ampicillin (0.38 l/kg), and 
ibuprofen (0.15 l/kg).7-9 These drugs were conjugated with NIR dye and then 
topically applied via spraying on the surface of an HCT116-luc liver tumor and 
transanally applied via the anus into the descending colon of colon tumor-bearing 
mice. Ralo-FCR675 can penetrate more deeply into the tissues than other drug-dye 
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preferentially observed in tumor lesions. 
The topical application of Ralo-FCR675 caused preferential distribution in tumor 
tissue, rather than in normal tissue. First, Ralo-FCR675 penetrated more deeply into 
tumor tissue than other drug-dye conjugates presumably due to its high Vd (Figure 
5.7, 5.8). In addition, drug-dye conjugates selectively accumulated in tumor tissues 
over normal tissues (Figure 5.7, 5.8), which is attributed to a much denser and 
thicker ECM network in tumor tissues and denser vascularization in peripheral 
tumor tissues unlike normal tissue (Figure 5.9).  
Raloxifene-dye conjugates could aid surgeons as contrast agents for delineating 
the margins of a tumor mass for tumor resection and appropriate biopsy.15 It is 
worth noting that Ralo-FCR675 selectively accumulated in tumors as compared to 
normal tissues. Drug-dye conjugates were devised as a solution that is amenable to 
spraying in vivo, thus interfacing more readily with intraoperative and endoscopic 
procedures. Drug-dye conjugates can be topically applied via spraying to surgically 
exposed lesions at risk, making exposed lesions accessible to fluorescence 
detection16. In addition, the short incubation time (3 min) required for fluorescence 
detection does not require the surgeon to wait with exposed lesions. The 
fluorescence lasts sufficiently long (12 h), maintaining > 90% fluorescence intensity 
(data not shown). This long-lasting fluorescence could enable various interventional 
procedures, such as tumor resectioning or endoscopic biopsy in clinical settings. To 
detect the tumor foci at the margins of the tumor mass, FCR675 dye in the NIR 
fluorescence spectrum (650–900 nm) provides benefits such as relatively low 
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autofluorescence and high tissue penetration, allowing for highly sensitive imaging 
in deep tissue.17, 18 
Combining raloxifene with a therapeutic drug has the potential to selectively 
improve local delivery to the tumor center, contributing to overcoming drug 
resistance. Ralo-FCR675 penetrated most deeply into tumor tissue. Limited drug 
penetration through tumor tissue precludes exposing all the target cancer cells to a 
lethal concentration of a drug. This has been considered a primary reason for 
chemotherapy resistance leading to treatment failure.19, 20 Therefore, using 
raloxifene as a delivery carrier for a therapeutic drug could enhance drug 
penetration into the tumor core, thereby overcoming chemotherapy resistance. 
Combining raloxifene with an imaging agent or a therapeutic drug could be 
applied as the mode of local delivery. The local delivery of a therapeutic drug has 
recently attracted much interest with the development of highly technological 
medical devices such as endoscope, laparoscopic, or robotic instruments. Local 
delivery presents many advantages, including reduced dosage and only local 
exposure, potentially minimizing the risk of systemic side effects.21 In fact, the local 
injection of the mitomycin C-dextran conjugate to the tumor sites led to decreased 
systemic toxicity.22 Drug-dye conjugates were topically applied to liver tumors in 
this study, which could be translated to patients’ oral cavity for clinical applications.  
Known drugs have the advantage of accelerating clinical translation as contrast 
agents. Modified drugs are certainly considered a new area in regulatory approval 
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for human use.23 However, all drugs used in clinical settings come with practitioners’ 
knowledge of the pharmacokinetics, biodistribution, and side effects in humans, 
thereby reducing translational risk. Most drugs have their Vd values evaluated in 
animals and in early-phase clinical trials before they can be introduced into a 
clinical setting. Factors affecting Vd include the solubility and plasma-binding 
capability of drugs, which result in Vds displaying a wide range of values.24 The 




Four drug-dye conjugates were synthesized by coupling the NIR dye FCR675 
with four drugs with different Vd values: raloxifene, scopolamine, ampicillin, and 
ibuprofen. Topically applied Ralo-FCR675 also rapidly penetrated to the tumor’s 
maximum depth and, importantly, it preferentially accumulated in the tumor lesions, 
which enabled the visualization of the tumor. Fluorescently labeled drugs with high 
Vd, such as raloxifene, have the potential to rapidly detect tumors, contributing to 
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Imaging of tumor-associated macrophages 






Macrophages are phygocytic cells in the immune system and respond to local 
environmental cues. Macrophages are categorized as classically activated 
macrophages (M1 macrophages) or alternatively activated macrophages (M2 
macrophages).1, 2 M1 macrophages are activated by lipopolysaccharide or 
interferon-γ, producing pro-inflammatory mediators and exerting antitumor 
cytotoxicity.3 On the other hand, M2 macrophages are activated by stimulation with 
interleukin (IL)-4 and IL-13, secreting a wide range of angiogenic growth factors 
and secreting immunosuppressive cytokines. Recent, compelling evidence indicates 
that tumor-associated macrophages (TAMs), possessing M2-like qualities, play a 
significant role in promoting tumor angiogenesis, cell invasion, tumor growth, and 
metastasis in many human cancers, including colon, breast, skin, and lung.4, 5 In 
particular, the extent of TAM infiltration within tumors generally correlates with 
poor prognosis, for example, in high-risk breast cancer.6 Therefore, TAMs can be a 
unique target for tumor imaging, facilitating clinical applications for the prognosis 
and treatment of tumors.7 
TAMs are known to over-express class A scavenger receptors (SR-A).8, 9 SR-A is 
included in a family of scavenger receptors among membrane receptors and is a 
multifunctional receptor that binds with various negatively charged 
macromolecules.10 Dextran sulfate (DS), a negatively charged derivative of dextran, 
performs as a ligand for SR-A.11 Previously, DS nanoprobes (DSNPs) were 
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developed to detect SR-A-positive macrophages in rheumatoid arthritis. In this 
study, NIR fluorophore-labeled DSNPs were prepared and characterized. The in 
vitro cellular uptake of DSNPs was investigated in MDA-MB-468 cancer cells, 
RAW264.7 macrophage cells, and isolated TAM. In vivo body distribution of 
DSNPs was observed in MDA-MB-468 tumor-bearing mice. TAMs in excised 
tumors were confirmed with immunohistochemical analysis using anti-CD204 
antibody, which were compared with the fluorescence signal from the DSNPs. 
 
6.2. Experimental section 
6.2.1. Materials 
DS sodium salt (mw = 36–50 kDa) was obtained from MP Biochemicals, LLC 
(Santa Ana, CA). FPR675 (excitation and emission maximum of 674 nm and 699 
nm, respectively) was purchased from Bioacts (Incheon, Korea). 4-
Dimethylaminopyridine (DMAP), 4-nitrophenyl chloroformate, and 5β-cholanic 
acid were purchased from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS) 
was purchased from Invitrogen Canada (Burlington, ON, Canada), and RPMI 1640 
medium and Dulbecco's modification of Eagle's medium (DMEM) were obtained 
from Gibco (Grand Island, NY). Monoclonal mouse anti-CD68 antibody was 


































conjugated with FITC and monoclonal mouse anti-CD204 (anti-SR-A) conjugated 
with FITC were purchased from Abcam (Cambridge, MA) and Novus Biologicals 
(Santa Cruz, CA), respectively. Collagenase was purchased from Sigma-Aldrich. 
5(6)-Carboxyfluorescein N-hydroxysuccinimidyl ester (CFSE) Cell Labeling Kit 
was purchased from Abcam. 
 
6.2.2. Preparation of dextran sulfate-based nanoprobes 
For fluorophore labeling, FPR675 (2 mg, 1.7 µmol) was added dropwise to the DS 
in dimethyl sulfoxide (DMSO; 200 mg/ 80 ml).12 The resulting solution was stirred 
for 24 h at room temperature (RT) and then dialyzed against distilled water (DW) 
with a cellulose membrane (MWCO = 6–8 kDa) for 72 h, resulting in FPR675-
labeled DS. Amphiphilic FPR675-labeled DS-5β-cholanic acid conjugates were 
synthesized by chemically conjugating hydrophobic bile acid (5β-cholanic acid) to 
water-soluble FPR675-labeled DS. FPR675-labeled DS (100 mg, 0.262 mmol) was 
dissolved in DSMO/pyridine (1:1, v/v; 15 ml), which was added with 4-nitrophenyl 
chloroformate (158 mg, 0.786 mmol) and DMAP (9.6 mg, 0.0786 mmol) at 0 oC 
and argon atmosphere. After reacting for 4 h, the mixture was isolated through 
precipitation with ether/ethanol (1:1, v/v; 300 ml). The precipitate was filtered and 
washed with ether. The 4-nitrophenyl-activated FPR675-labeled DS dissolved in 
DMSO/pyridine (2:1, v/v) was mixed with aminoethyl 5β-cholanoamide (13. 81 mg, 
0.0356 mmol) that was converted from 5β-cholanic acid.13 The resulting solution 
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was stirred for 48 h at 50 oC and argon atmosphere and then dialyzed against 
water/methanol mixture (1:4, v/v) with a cellulose membrane (MWCO = 12–14 
kDa) for 72 h. The FPR675-labeled DS-5β-cholanic acid conjugate (1 mg/ml) was 
sonicated with a probe-type sonicator (Ultrasonic Processor, GEX-600) in DW, 
resulting in well-dispersed FPR675-labeled DSNPs. 
 
6.2.3. Characterization of dextran sulfate-based nanoprobes 
The mean diameter and size distribution of DSNPs in DW were observed with 
dynamic light scattering (DLS) at 25C. DSNPs’ morphology in DW (1 mg/ml) was 
assessed with transmission electron microscopy (TEM, CM30 electronmicroscope, 
Philips, CA). TEM analysis was performed at 200 kV. The sample solution was 
placed on the grid for 2 min and excess solution was blotted with filter paper. For 
staining, the grid was placed on a drop of 2% (w/v) uranyl acetate. The zeta 
potentials of DSNPs (1 mg/ml) in DW were measured with an ELS-8000 
eletrophoretic light scattering spectrometer (Ostuka, Electronics, Japan).  
 
6.2.4. Isolation of tumor-associated macrophages 
All animal experimental procedures were in compliance with the institutional 
guidelines of Korea Institute of Science and Technology and the relevant laws. 
TAMs were prepared as described by Solinas et al.14, 15 Briefly, MDA-MB-468 cells 
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(1  106 cells/mouse) suspended in 50 l of sterile saline were injected 
subcutaneously into the flank of BALB/c mice (20 g, Orient, Seoul, Korea). When 
tumors reached approximately 7.0 ± 0.5 mm in size, they were harvested from 
sacrificed MDA-MB-468 tumor-bearing BALB/c mice under sterile conditions to 
isolate TAMs. Excised tumors were chopped into small pieces, and then incubated 
with serum-free RPMI 1640 containing collagenase (1 mg/ml) for 1 h at 37°C. The 
digested tissues were filtered using a cell strainer with 70 µm pores to generate a 
single-cell suspension. Then, cells were recovered by centrifugation at 1000 rpm for 
10 min, washed twice with phosphate-buffered saline (PBS), and resuspended in 
serum-free RPMI 1640. The cells were incubated for 1 h at 37°C, and then 
unattached cells were washed away. Isolated TAMs were maintained in RPMI 1640 
medium containing 10% (v/v) FBS and penicillin G (100 U/ml)/streptomycin (100 
μg/ml) at 37C, 5% CO2.  
For characterization of the isolated TAMs, cells were plated in 35 mm cover-glass 
bottom dishes and incubated for 48 h. After washing with PBS, the cells were 
permeabilized and blocked. Cells were treated with monoclonal mouse anti-CD204 
antibody (1:100 dilution) for overnight 4C, and then with goat anti-mouse IgG-
FITC (1:100 dilution) for 1 h. Then, the cells were stained with 4',6-diamidino-2-
phenylindole (DAPI). The cells were observed using IX81-ZDC focus drift 
compensating microscope (Olympus, Tokyo, Japan).  
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6.2.5. Cytotoxicity and cellular uptake 
MDA-MB-468, a breast cancer cell line, and RAW264.7, a macrophage cell line, 
were maintained in RPMI 1640 medium containing 10% (v/v) FBS and penicillin G 
(100 U/ml)/streptomycin (100 μg/ml) at 37C, 5% CO2. The DSNPs’ cytotoxicity 
was evaluated using Cell Counting Kit-8 (CCK-8) assay. In brief, RAW264.7 or 
MDA-MB-468 cells (1  104 cells/well) were seeded in a 96-well microplate, and 
cultured for 24–36 h. The DSNPs (5, 25, 50, 100 μg/ml) were added to each well of 
the cell culture and incubated for 24 h. CCK-8 solution was added to each well of 
the cell culture and incubated for 2 h, and absorbance was observed at 450 nm with 
a plate reader. Cell viability was expressed as a percentage relative to the untreated 
control cells.  
MDA-MB-468 (1×105 cells/dish), RAW264.7 (1×105 cells/dish), and the isolated 
TAM (1×105 cells/dish) were plated in 35 mm cover-glass bottom dishes and grown 
to 80% confluence. The cells were washed twice with PBS (pH 7.4) and then 
incubated with serum-free medium containing DSNPs (200 nM) for 6 h. The cells 
were washed with PBS (pH 7.4) twice, fixed with fresh 4% (v/v) paraformaldehyde 
at RT for 5 min, and mounted with Fluoromount-G™ (Southern Biotech, 
Birmingham, AL). Cellular uptake of DSNPs was observed using a confocal laser 
scanning microscope (Leica SP5, Leica Microsystems, Buffalo, Grove, IL). 
To establish co-culture system of macrophage cells (RAW264.7) and cancer cells 
(MDA-MB-468), two types of cells were maintained in RPMI 1640 medium 
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containing 10% (v/v) FBS and penicillin G (100 U/ml)/streptomycin (100 μg/ml) at 
37C, 5% CO2, respectively. To distinguish cancer cells and macrophage cells, the 
cancer cells were labeled using 5(6)-carboxyfluorescein N-hydroxysuccinimidyl 
ester (CFSE) cell labeling kit according to the manufacturer’s protocol. A co-culture 
of macrophage cells and cancer cells was prepared by seeding 2 × 105 CFSE-labeled 
cancer cells and 2 × 105 macrophage cells onto 35 mm culture dish. The cells were 
cultured in RPMI 1640 medium containing 10% (v/v) FBS and penicillin G (100 
U/ml)/streptomycin (100 μg/ml) at 37C, 5% CO2 for 24 h. The cells were washed 
twice with PBS (pH 7.4) and then incubated with serum-free medium containing 
DSNPs (200 nM) for 4 h. The DSNP uptake in the co-culture system was analyzed 
using a confocal laser scanning microscope. 
6.2.6. In vivo and ex vivo fluorescence imaging 
When MDA-MB-468 tumors reached approximately 7.0 ± 0.5 mm in size, DSNPs 
(1 mg/ml in 100 μl of PBS) was injected via tail vein to the tumor-bearing mice. In 
vivo NIR tomographic images were acquired with an eXplore Optix system 
(Advanced Research Technologies Inc., Montreal, Canada). For quantitative 
analysis, the total photon counts in tumors were calculated using the region of 
interest (ROI) measurement of the Analysis Workstation software program 
(Advanced Research Technologies Inc.). Values are presented as means  standard 
deviations for groups of three animals. A one-way analysis of variance (ANOVA) 
was used for the comparison of continuous variables between groups. After in vivo 
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imaging studies, the mice were sacrificed, and the liver and tumor were excised and 
imaged using a Kodak image station (4000MM; Kodak, New Haven, CT) equipped 
with a special C-mount lens and FPR675 bandpass emission filters.  
 
6.2.7. Histological analysis 
For the histological evaluation, each excised tumor was divided into two pieces, 
and one was fixed in 4% (v/v) buffered formalin and embedded in paraffin. The 
other was embedded in optimum cutting temperature (OCT) compound for cryo-
section preparation. The paraffin-embedded specimens were cut into 5 m-thick 
sections, and they were stained with hematoxylin and eosin (H&E) or used for 
immunohistochemistry (IHC) against CD68. For IHC, the paraffin-embedded 
sections were deparaffinized and rehydrated with xylene, graded ethanol, and PBS 
(pH 7.4). Endogenous peroxidase was blocked by incubating the sections in 3% 
hydrogen peroxide in PBS for 20 min at RT. After being washed three times, each 
section was then incubated with primary antibodies to CD68 (1:200 dilution) for 2 h 
at RT. HISTOSTAIN®-PLUS Kit (Invitrogen, Carlsbad, CA) was applied to detect 
binding of primary reagents. Sections were counterstained with Harris’s 
hematoxylin (Sigma) and examined using light microscope (BX51TF, Olympus). 
The 8 m-thick frozen sections were prepared for fluorescence microscopic 
imaging of FPR675-labeled DSNPs and for IHC against F4/80 (1:200 dilution) or 
CD204 (1:200 dilution). The slices were washed with DW, permeablized with H2O2 
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solution, and then incubated with primary antibodies to F4/80 (1:200 dilution) or 
CD204 (1:200 dilution) for 2 h at RT. The slides were washed with PBS and 
mounted. The slides were observed under the IX81-ZDC focus drift compensating 
microscope without histological stains. 
 
6.3. Results 
6.3.1. Characterization of dextran sulfate-based nanoprobes 
As TAM-targeting nano-sized carriers, amphiphilic FPR675-labeled DS-5β-
cholanic acid conjugates were self-assembled in DW. TEM and DLS analyses 
displayed that DSNPs formed a spherical nanoparticle and that it was 188.5 ± 5.27 
nm in diameter (Figure 6.2). The zeta potential of DSNPs was -47.5 ± 1.26 mV in 
DW. No significant changes in the size and distribution of DSNPs were observed in 
PBS for two weeks, which demonstrates the long-term stability of DSNPs in 
physiological conditions (data not shown). DSNPs’ cytotoxicity in RAW264.7 and 
MDA-MB-468 cells was determined using CCK-8 assay (Figure 6.2 c). DSNPs 
exhibited cell viability > 95% at concentrations up to 100 g/ml. 
 
6.3.2. Cellular uptake of dextran sulfate-based nanoprobes 
The cellular uptake behavior of DSNPs was investigated using MDA-MB-468 
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cancer cells, RAW264.7 macrophage cells, and isolated TAM. TAM was isolated 
from MDA-MB-468 tumors in BALB/c mice. This isolated TAM was stained 
positively with CD204. Most adherent cells were TAMs as assessed by morphology 
and CD204 (M2 macrophage marker) positivity (Figure 6.3 a). After incubating 30 
min of DSNPs in various types of cells, a very low fluorescence signal from DSNPs 
was detected in the MDA-MB-468 cells, whereas a strong fluorescence signal was 
detected in the RAW264.7 cells and the isolated TAM (Figure 6.3 b). In the case of 
FPR675-labeled glycol chitosan nanoparticles (chitosan nanoprobes; CNPs), which 
have been evaluated as good optical probes for targeting of tumor cells, they 
showed high uptake into MDA-MB-468 cells and low uptake into RAW264.7 cells 
and the TAMs. In the co-culture system of macrophage cells and cancer cells, 
DSNPs entered preferentially in macrophage cells, indicating that DSNPs possess 
targeting capacity for macrophage cells. 
 
6.3.3. In vivo distribution of dextran sulfate-based nanoprobes 
At 1 h post-injection of DSNPs (5 mg/ml) through the tail vein, the fluorescence 
signals of tumor and liver sites were slightly increased. Then, tumor and liver sites 
were clearly delineated from the surrounding tissues 5 h post-injection of DSNPs 
and slowly diminished afterwards (Figure 6.4 a). In ex vivo images of excised liver 
and tumor at 24 h post-injection of DSNPs, higher NIR fluorescence intensity was 
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6.3.4. Immunohistochemistry of tumor tissues  
To reach approximately 7.0 ± 0.5 mm in diameter, tumor were grown for 6 weeks. 
Tumoral and peritumoral tissues from MDA-MB-468 subcutaneous tumors were 
analyzed with the histology and the IHC against CD68 (macrophage marker).16 In 
H&E, a large number of infiltrated macrophages were detected in the peritumoral 
area, while small number of macrophages was detected in the tumoral area (Figure 
6.5 a). Immunohistochemical analyses demonstrated that CD68-positive 
macrophages were present mainly in the peritumoral area and slightly in the tumoral 
area. In addition, the fluorescence signal from DSNPs (red) in the tumor tissue was 
co-localized both with those of F4/80 (green) or CD204 (green), respectively 
(Figure 6.5).  
 
6.4. Discussion 
Among various immune cells, TAMs are the crucial players in tumor 
microenvironment for mediating immuno-suppression.5 TAMs are infiltrated into 
the tumor site by chemokines, cytokines, and other tumor-derived factors, which 
preferentially localize at the tumor-stroma interface.2 TAMs have a tumor-
supportive M2 function, which is differentiated from a tumor-supportive M1 
function. They secrete a wide range of angiogenic growth factors including vascular 
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metalloproteinases and cathepsins, promoting tumor progression and metastasis. In 
addition, they overexpress immunosuppressive cytokines such as transforming 
growth factor (TGF)-β and IL-10, which hampers the infiltration of antitumor 
immune cells and further encourages a microenvironment conducive to tumor 
progression. Recently, there has been increasing clinical and preclinical evidence 
associating abundance of TAM with poor prognosis.1, 17-19 Therefore, the monitoring 
of TAM infiltration in tumors could extend the clinical applications regarding 
cancer prognosis. Moreover, imaging of TAMs in vivo could be helpful in 
elucidating their role in cancer progression and evaluating macrophage-targeted 
treatment.  
So far, TAMs have been predominantly identified using CD68 immunostaining.10, 
20 However, CD68 is a marker used to assess TAM, which cannot distinguish the M2 
phenotype from monocytes and subpopulations of macrophages. Recently, CD204 
(SR-A) has been recognized as a useful marker for the detection of TAMs. CD204 
has been confirmed to be a specific marker for the immunosuppressive M2 
macrophages useful for discriminating polarized M2 macrophages from M1 
macrophages. 10, 20 CD204 has been reported to be strongly expressed in the TAMs. 
In addition, CD204-positive TAMs were significantly correlated with poor 
prognosis and malignant phenotypes in patients with glioma, pancreatic cancer, and 
ovarian epithelial tumors. In the immunostaining experiments assessing TAM, the 
antibodies against CD68, F4/80, and CD204 were utilized. Considering the diverse 
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favorable to utilize two or more markers for detecting TAMs. 
 
6.5. Conclusions 
FPR675-labeled dextran sulfate-based nanoprobes (DSNPs) were developed to 
detect TAMs in tumors. DSNPs were significantly uptaken into RAW264.7 
macrophage cells and isolated TAMs, not in MDA-MB-468 cancer cells. 
Immunohistochemical analysis using and CD68 (macrophage marker) displayed 
that TAM infiltration was mainly observed in peritumoral area of MDA-MB-468 
tumors. In addition, DSNPs mainly target CD204 (M2 macrophage marker)-positive 
TAMs. This suggests that DSNPs could be potentially utilized to image TAM 
infiltration in tumors.  
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분자영상은 21세기 암 치료에 있어서 매우 중요한 요소이다. 분자영상
은 살아있는 상태에서 세포 또는 분자 수준에서 일어나는 질병과 관련 
있는 변화를 가시화하여 눈으로 보여주는 기술이다. 분자영상은 암을 보
다 조기에 발견할 수 있게 하여 치료 효율을 높이는데 기여한다. 이 외
에도 분자영상은 치료효과를 실시간으로 평가하고, 종양의 제거 수술 중
에 종양의 위치와 크기를 빠르고 정확하게 보여주는데 기여할 수 있다. 
여러 분자영상 방식 중에서 광학영상 방식은 적은 양의 타깃 물질도 민
감하게 감지할 수 있으며 실시간 이미징 및 다양한 형광체를 이용한 다
중 이미징이 가능하다는 점에서 장점이 있다. 
 오랫동안 암 연구는 암세포에 있는 특정한 생체분자를 표적화하여 연
구해왔다. 그러나 암은 암세포만 모여있는 것이 아니라 혈관 관련 세포, 
면역세포, 섬유아세포, 단백질분해효소, 성장인자, 세포외기질 등의 다양
한 요소가 종양세포 주위에 혼재하여, 종양이 성장하거나 전이하는데 큰 
역할을 한다고 알려졌다. 이렇게 종양세포를 둘러싸고 있는 다양한 요소
들을 총칭하여 종양미세환경이라고 한다. 최근 종양세포와 더불어 종양




본 논문은 암의 발생과 진행 과정에 따라 변화하는 암의 중요 요소들을 
가시화하는 분자영상에 대한 연구로, 암에 대한 이해도를 높이고 암의 
진단 및 치료에 기여함을 목적으로 하였다. 본 논문에서 암세포와 주변
미세환경의 다양한 요소, 단백질 분해효소, 성장인자 수용체, 세포외기질, 
종양조직, 대식세포를 표적으로 하는 광학 영상 실험을 수행하였다. 
첫 번째로 암의 전이과정에서 과발현되는 특성을 지닌 단백질분해효소 
카셉신을 이미징하였다. 카셉신에 특이적으로 반응하는 기질 펩타이드와 
근적외선 형광, 소광체로 이루어진 펩타이드 프로브를 암 표적성을 가진 
키토산 나노입자의 표면에 도입함으로써 카셉신 나노프로브를 합성하였
다. 카셉신 나노프로브는 카셉신-B에만 특이적으로 활성화되어 카셉신-
B에 민감도 높은 이미징이 가능하였다. 카셉신 나노프로브는 전이성 간
암, 전이성 폐암, 전이성 복막암에 적용되어, 카셉신 나노프로브를 이용
한 전이암 이미징의 가능성을 보여주었다. 
두 번째로 종양세포 표면에 과량 존재하는 수용체 중 상피성장인자 수
용체를 표적으로 이미징을 시도하였다. 수용체를 타깃으로 하는 이미징
은 수용체에 대한 특이성이 높은 프로브를 사용할 수 있다는 장점이 있
다. 상피성장인자 수용체의 천연 리간드인 상피성장인자를 사용하여 광
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학프로브 (상피성장인자 나노프로브)를 합성하였다. 상피성장인자 나노프
로브는 세포내로의 이입후 리소좀에서의 분해를 통해 형광이 나타났다. 
세포 및 동물 이미징 실험을 통해, 상피성장인자 나노프로브가 상피성장
인자 수용체에 대한 뛰어난 특이성을 가지고, 종양의 이미징을 가능하게 
함을 보여주었다. 
세 번째로 세포외기질에 존재하는 라이실-산화효소를 민감하게 검출할 
수 있는 방법을 연구하였다. 라이실-산화효소는 세포외기질의 구성물질 
중 가장 많은 비중을 차지하는 콜라겐 분자에 포함된 라이신을 알리신으
로 변화시키는데 관여하는 효소이다. 알리신 또는 라이신에 대한 결합 
반응성이 높은 특징을 가진 알리신은 주변 콜라겐의 라이신이나 알리신
과 반응하여 콜라겐의 교차결합을 유도하여, 종양의 단단함을 증가시킨
다. 단단한 종양은 종양의 악성화 및 전이의 가능성을 높이기 때문에, 라
이실-산화효소를 민감하게 검출하는 것은 중요하다. 검출을 위해 금나노
입자의 표면플라즈몬공명 현상으로 인한 색깔 및 흡수 파장이 변화되는 
성질을 이용하였다. 금나노입자의 표면에 라이실-산화효소에 반응하는 
펩타이드를 도입(라이실-산화효소-금나노입자)하여, 라이실-산화효소에 
의해 금나노입자의 뭉침현상으로 인해 금나노입자 용액의 색깔 및 흡수 
파장의 변화가 일어날 수 있도록 고안하였다. 이를 이용하여, 세포의 상
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등액과 종양에서 추출한 단백질에서 라이실-산화효소의 정량적인 분석이 
가능함을 보여주었다. 
네 번째는 수술 중 종양의 위치와 크기를 빠르고 정확히 보여줄 수 있
도록 국부 도포 방식으로 사용할 수 있는 이미징 프로브를 합성하였다. 
조직을 잘 투과하는 프로브를 만들기 위해, 분포용적 수치가 다양한 약
물에 근적외선 형광체를 도입하여 간암모델의 간 표면에 뿌려주었다. 이
미징한 결과 분포용적 수치가 높은 약물과 형광의 결합체는 주로 종양부
위에 존재하였고, 종양 내부로 빠르고 깊이 침투한 것이 관찰되었다. 높
은 분포용적을 가진 약물은 종양과 정상조직을 구분할 수 있는 유용한 
인자가 될 수 있을 것으로 생각한다. 
마지막으로 종양미세환경 요소 중 암의 성장을 돕는 역할을 하는 종양 
연관 대식세포의 생체내 이미징을 시도하였다. 종양 연관 대식세포 표면
에 과량 존재하는 스카빈저 수용체 (scavenger receptor class A, 
SR-A)의 리간드인 황산 덱스트란을 이용하여 광학 프로브를 합성하였
다. 본 광학 프로브는 종양세포로의 이입은 잘 이루어지지 않았지만, 대
식세포와 종양 연관 대식세포로의 이입은 잘 이루어졌다. 본 광학 프로
브를 쥐의 꼬리정맥을 통해 종양모델에 주입한 후 실시한 조직학 검사를 
통해 광학 프로브가 주로 SR-A 수용체를 가지고 있는 종양 연관 대식
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세포를 표적하고 있음을 확인하였다.  
암은 여러 요소들이 관여하고 있는 질병이다. 한가지 요소만을 표적으
로 이미징하기 보다는 다양한 요소들을 표적화하는 연구를 통해서, 보다 
민감하고 특이적인 암 진단을 이룰 수 있을 것으로 기대한다. 
주요어: 분자영상, 암영상, 광학영상, 종양미세환경, 약물전달시스템 
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